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CHAPTER I 
 
INTRODUCTION 
 
Antibiotics 
 In 1896, Ernest Duchesne discovered that Penicillium mold could effectively 
inhibit the growth of E. coli and prevent typhoid infections if injected concomitantly with 
the bacteria.  Alexander Fleming’s work in the 1920s on the same mold lead to a 
revolution in modern medicine.  In a few years, for the first time in history, tuberculosis, 
pneumonia, and a myriad of other infections could be easily treated.  Since Fleming’s 
seminal observation, chemists and biologists have worked to isolate, characterize, and 
synthesize molecules capable of inhibiting microbial growth.  Compounds have been 
designed to disrupt three main pathways necessary for bacterial survival.  These include 
inhibition of DNA, protein, and cell wall synthesis (Figure 1).  Quinolones interfere with 
topoisomerases, which regulate DNA supercoiling and thus transcription.  Macrolides 
and related drugs disrupt protein synthesis by binding ribosomes.  The third class targets 
enzymes involved in bacterial cell wall synthesis.   These molecules have decreased risk 
of side effects since there are no equivalent human enzymes. 
 Cell wall biosynthesis is the process by which microbes assemble the complex 
molecular structure which allows them to resist osmotic pressure and other environmental 
stresses.  It begins with the reaction of phosphoenolpyruvate (PEP) with uridine 
diphospho-N-acetyl-D-glucosamine, generating UDP-N-acetylenolpyruvyl glucosamine  
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Figure 1.  Cellular targets of the major classes of antibiotics. 
 
(Figure 2) (1).  This is reduced by NADPH to UDP-N-acetyl muramic acid.  A series of 
amino acids are added sequentially by the MurC-MurF enzymes.  The precursor is then 
localized to the cell membrane via transfer from the uridyl carrier to the phosphate group 
of a C55-isoprenoid alcohol phosphate by MraY, generating Lipid I.  N-acetyl- D -
glucosamine is then transferred from uridine to the lipid-linked N-acetylmuramic acid 
residue by MurG, generating Lipid II.  A series of steps add peptide cross-links between 
lipid chains, leading to the generation of mature peptidoglycan. 
Many steps in peptidoglycan synthesis have been targets of antimicrobial 
therapies.  Penicillin and other β-lactams are structural analogs of D-alanyl-D-alanine and 
inhibit enzymes which recognize this moiety, preventing further catalysis toward mature 
cell wall.  Vancomycin and related drugs bind to the D-alanyl-D-alanine portion of the  
cell wall precursor, also preventing further catalysis.  Bacitracin inhibits MraY and 
prevents transfer of N-acetylmuramyl peptide to the cell membrane.
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Figure 2.  Reactions of the formation of bacterial cell wall components. 
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Antibiotic Resistance 
 Although antibiotics have undoubtedly cured countless infections and saved 
millions of lives world-wide, bacteria continue to wreak havoc in the medical 
community, creating a $25 billion market for antibiotics annually in the US alone (2).  
Resistance can be acquired from a variety of sources—plasmids, bacteriophage, and free 
DNA—containing transposons and other resistance elements (Figure 3A).  Resistance 
genes may be incorporated into the genomic material or remain separate as a plasmid.   
Resistance can be achieved through a variety of mechanisms.  Spontaneous 
resistance can occur through random mutations in target proteins which are capable of 
carrying out their native function while resisting attack by an antibiotic.  Alternatively, 
modulation of uptake or efflux systems by mutation of receptors expressed in the cell 
membrane can prevent antibiotic molecules from entering or hasten their export from the 
cell.  Cytosolic proteins capable of sequestering antibiotic molecules can prevent them 
from reaching their cellular target.  Finally, expression of proteins which can alter or 
decompose an antibiotic into an inactive form also protects the bacteria (Figure 3B). 
The resistance problem has affected every class of antibiotic (Table 1).  With the 
exception of vancomycin, bacterial resistance emerged within a few years of an 
antibiotic’s introduction into the clinic.  Identification of β-lactamases, which break down 
penicillin and related compounds, now limit the effectiveness of these wonder drugs.  
Even vancomycin, used as a last resort to treat resistant infections, is susceptible.  A 
plasmid-encoded resistance cassette allows bacteria to produce a modified cell wall 
precursor (UDP-muramyl-tetrapeptide-D-lactate) which has low affinity for vancomycin 
(3). 
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Figure 3.  A.  Modes of acquisition of antibiotic resistance elements.  B.  Methods 
bacteria utilize to protect themselves from antibiotic.  Adapted from (4). 
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Table 1.  Relationship between discovery, introduction into the clinic, and 
identification of resistance for selected antibiotics.  Taken from (3). 
 
Antibiotic Discovered Introduced in the clinic Resistance identified 
Penicillin 1940 1943 1940 
Streptomycin 1944 1947 1947 
Tetracycline 1948 1952 1956 
Erythromycin 1952 1955 1956 
Vancomycin 1956 1972 1987 
 
What is being done to resolve the resistance problem?  Medical and scientific 
professionals are educating themselves and the public on the proper use of antibiotics.  
Some health professionals have also begun withholding treatment with new antibiotics 
such as Zyvox except as a last resort (2).  New treatments include development of 
narrow-spectrum agents or enzyme inhibitors which could be utilized in combination 
therapies with resistant organisms (5). 
 
Fosfomycin 
In 1969 Hendlin and coworkers reported the discovery and synthesis of a novel 
phosphonate isolated from cultures of Streptomyces which was effective as an antibiotic 
against Gram positive and negative bacteria (6, 7).  The compound, (1R, 2S)-1,2-
epoxypropylphosphonic acid, or fosfomycin, acted by irreversibly inhibiting uridine-5’-
diphospho-N-acetyl-D-glucosamine-3-enolpyruvyltransferase (MurA), the enzyme which 
catalyzes the first step of cell wall biosynthesis (Figure 2) (8).  It is known that binding of 
substrate (UDPGlcNAc) to MurA induces large conformational changes, and it has been 
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shown that UDPGlcNAc binding is required for fosfomycin inactivation to occur.  
Inactivation by fosfomycin occurs in a bimolecular mechanism (Figure 4) involving the 
formation of a reversible enzyme-substrate complex followed by the irreversible covalent 
modification of the enzyme by fosfomycin (9).   
Inactivation has been measured in two ways.  MurA reacts with 8-anilino-1-
naphthalene sulfonate (ANS) such that ANS fluorescence is quenched upon substrate 
binding to enzyme.  Addition of fosfomycin to MurA•UDP-GlcNAc produces a structural 
change with a bimolecular rate constant k*struc of 85 M-1s-1.  Inactivation studies of the 
same complex in the presence of fosfomycin produces a similar rate constant k*inact of 
104 M-1s-1.  The similarity of these independently measured rate constants indicates that 
fosfomycin-induced structural changes of MurA and enzyme inactivation occur in 
parallel. 
 
 
 
 
 
 
Figure 4.  Mechanism for the inactivation of MurA by fosfomycin.  S1 is UDP-GlcNAc. 
 
 
X-ray crystal structures obtained with UDP-GlcNAc and fosfomycin present in 
the MurA active site show the antibiotic adducted to Cys115 (Figure 5A).  A variety of 
positive residues, necessary for binding phosphoenolpyruvate, coordinate to fosfomycin 
equally well (Figure 5B). 
MurA    +    S1
KD (S1)
88 µM
E  S1
fosfomycin
I-E*  S1
k*
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Figure 5.  A.  Ribbon representation of MurA (from 1UAE.pdb).  UDP-GlcNAc, 
fosfomycin, and several active site residues are shown as sticks.  B.  Enlargement of the 
active site, showing fosfomycin bonded to Cys115.  UDP-GlcNAc (top right) is shown, 
as are R120, R397, K22 and C115.  Figures were made using PyMOL (10). 
 
B 
A 
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While fosfomycin is an excellent antibiotic—its mechanism of inactivation is 
irreversible and its target has no homologue in mammals, thus preventing side effects—it 
has not escaped the resistance problem.  Means of resistance to fosfomycin appeared 
shortly after it was introduced into the clinic.  Bacteria with mutations in the L-α-
glycerolphosphate (αGP) and hexose phosphate transport systems, which were both 
shown to be utilized in fosfomycin uptake, appeared (11-13).  Mutants of MurA also 
arose; these proteins were catalytically active but were resistant to modification and 
inactivation by fosfomycin (14).  Later, a third type of resistance appeared.  Researchers 
linked this resistance to a plasmid-encoded transposable element identified as Tn2921 
(15).  This resistance element was a 16 kDa soluble protein which caused a modification 
of fosfomycin (16) later determined to be conjugation with the tripeptide glutathione (γ-
Glu-Cys-Gly, GSH) (17). 
Early purification and characterization of this resistance protein indicated that it 
was a dimeric protein whose activity increased in the presence of divalent cations such as 
Mn++ and Co++ (18).  Subsequent research revealed that the protein, termed FosA, was a 
Mn++-dependent GSH transferase unrelated to canonical GSH transferases (19).  FosA 
also showed activation in the presence of monovalent cations such as K+.  The reaction 
catalyzed by FosA is shown in Figure 7. 
Sequence homologies of FosA and other catalytically unrelated enzymes revealed 
the existence of a previously unrecognized enzyme superfamily.  Enzymes in the family 
use conserved histidine and glutamate residues to bind metal ions which coordinate 
vicinal substrate oxygen atoms, thus facilitating catalysis (Figure 6).  This common 
mechanistic imperative lead to the family being dubbed the Vicinal Oxygen Chelate 
10 
(VOC) superfamily (20).  The VOC proteins contain conserved βαβββ structural motifs 
which pair to form a cupped-shaped metal binding site (Figure 6) (21). 
 
Genomic FosA Homologues 
After the identification and characterization of the plasmid-encoded fosfomycin 
resistance protein it was thought that other resistance proteins might exist in bacterial 
genomes.  To test this hypothesis, the FosA sequence was used to query bacterial genome 
databases in BLAST searches to identify any homologues.  This revealed the occurrence 
of a protein with approximately 30% identity to FosA in the genome of Bacillus subtilis.  
The yndn protein has subsequently been expressed and characterized (22).  Studies have 
indicated that this protein, named FosB, is regulated by the σW class of transcription 
factors.  These proteins are known to be involved in regulation of bacterial defense 
mechanisms against antimicrobials.  FosB also catalyzes a thiol transferase reaction with 
fosfomycin but utilizes L-cysteine as a thiol donor.  This is not surprising since most 
Gram positive bacteria lack the genes necessary for GSH synthesis.  Also, the protein has 
little activity with Mn(II), preferring Mg++ as its cofactor.  Unlike FosA, FosB shows no 
activation by monovalent cations. 
As other microbial genomes have become available, FosA homologues have been 
identified in Pseudomonas aeruginosa, Staphylococcus aureus, and Listeria 
monocytogenes, among others.  Characterization of purified enzymes has shown that the 
resistance proteins fall into three classes based on sequence homology, metal preferred 
for catalysis, and choice of nucleophile conjugated to fosfomycin.  Figure 7 shows 
relationships between the proteins as well as the reactions catalyzed by each class. 
11 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Ribbon diagrams and proposed mechanisms of VOC superfamily members.  
Note coordination of vicinal oxygen atoms in the substrates by the metal centers.  From 
top to bottom, glyoxalase I, extradiol dioxygenase, and FosA.  Generated from 
1MPY.pdb, 1F9Z.pdb, and 1NPB.pdb, respectively.  Glyoxalase I is shown with bound 
Ni++ ions (green spheres).  Ribbons colored by monomer. 
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Figure 7.  A.  Relationships between the fosfomycin resistance proteins as generated by 
ClustalW.  B.  Reactions catalyzed by each type of resistance protein. 
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This Work 
Research presented here reports experiments carried out to elucidate kinetic, 
structural, and mechanistic characteristics of the FosA homologue encoded in the genome 
of Pseudomonas aeruginosa as well as preliminary studies of a FosB protein from the 
genome of Staphylococcus aureus.  The PA1129 gene from P. aeruginosa shares a 60% 
identity with FosA, and it was thought that this protein could in fact be a genomic 
fosfomycin resistance protein.  Microbiological data support the existence of a resistance 
element in P. aeruginosa, as fosfomycin is often ineffective in treating urinary tract 
infections caused by the organism (23).  Several studies report unusually high minimum 
inhibitory concentrations (MICs) for fosfomycin for strains of P. aeruginosa (24-26).  
The gene was cloned from genomic DNA and the protein expressed, purified, and 
characterized.  Results indicate that, like the plasmid-encoded protein, PA1129 is a very 
efficient, manganese-utilizing GSH transferase specific for fosfomycin. 
Prior to structural characterization of PA1129, electron paramagnetic resonance 
(EPR) spectroscopy was utilized to probe the metal coordination of the E•Mn(II)•K 
complex in the presence and absence of phosphonates.  It had been shown previously that 
for FosA (Tn2921), the EPR spectrum of E•Mn(II)•K was dramatically altered upon the 
addition of fosfomycin but remained unchanged in the presence of glutathione (27).  In 
the absence of structural data of several site-directed mutants, circular dichroism was 
used to compare secondary structures of mutants to native protein.  Fosfomycin 
resistance could be mediated if effective inhibitors were developed for concomitant 
administration with the drug.  Analysis of a crystal structure of PA1129 with fosfomycin 
bound in the active site indicated that small phosphonates might competitively inhibit the 
14 
resistance proteins (28).  Research presented here focused on analysis of a panel of 
potential phosphonate inhibitors (Figures 8 and 9) as well as an oxidized form of 
glutathione (GSO3-) for inhibition of FosA.  Phosphonoformate, 2, was of particular 
interest as a minimal transition state analogue (Figure 8).  Also investigated was the 
ability of PA1129 to catalyze formation of either an enolate or a 1,2-GSH adduct with 
acetyl phosphonate, 4. 
 
 
 
 
 
 
 
 
Figure 8.  Reaction catalyzed by FosA comparing a proposed transition state with 
phosphonoformate, 2. 
 
 
 
 
 
 
 
 
2 
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Figure 9.  Compounds tested as inhibitors of FosA activity. 
 
While various biochemical methods including x-ray crystallography (28), electron 
paramagnetic resonance spectroscopy (29), and kinetic characterization have answered 
many questions regarding how fosfomycin binds to FosA and is activated for 
nucleophilic attack, little has been learned about how GSH is conjugated to the antibiotic.  
Work presented here reports the elucidation of a potential GSH binding site through 
manual docking of GSH to a FosA crystal structure followed by energy minimization of 
the docked complex.  Mutagenesis of potential binding and catalytic residues followed by 
kinetic characterization and GSH binding studies provide support for the proposed 
binding site. 
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Insight into the origin of this diverse protein family (Figure 7) has come from a 
FosX homologue from the genome of Mesorhizobium loti, a nitrogen-fixing bacterial 
symbiont of Lotus species.  The mlr3345 gene is located in a phosphonate utilization 
operon also found in E. coli, although an mlr3345 homologue is missing.  While 
presumably mlr3345 has a physiologic role in phosphonate metabolism, it has also been 
found to be a promiscuous fosfomycin resistance protein in vitro in that it catalyzes both 
hydrolase and GSH transferase reactions with fosfomycin.  However, it is not capable of 
conferring significant resistance to E. coli transformed with an expression plasmid.  It 
seems likely that this catalytically poor fosfomycin resistance protein evolved early in the 
divergence of fosfomycin resistance proteins from a common precursor.  This research 
has attempted to elucidate residues of importance in determination of substrate specificity 
and catalytic proficiency between the FosA and FosX classes of resistance proteins. 
The FosB proteins were identified as a class of fosfomycin resistance proteins 
which catalyze the addition of L-cysteine to fosfomycin in a Mg++-dependent manner.  A 
genomic protein from B. subtilis was cloned, expressed, and characterized previously 
(22).  BLAST searches of bacterial genomes using FosA as a query identified the 
presence of a putative fosfomycin resistance protein in Staphylococcus aureus which 
showed 62% identity to BS_yndn from B. subtilis.  This protein was cloned, expressed, 
purified, and characterized with respect to its substrate and metal preferences.  Results 
show that it is in fact a cysteine-utilizing, Mg++-dependent FosB. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Materials 
Escherichia coli BL21-DE3 cells were from Novagen (Madison, WI).   
Phosphonoacetic acid, 2-carboxyethylphosphonic acid, pyruvate, and tris(trimethylsilyl) 
phosphite were from Aldrich (Milwaukee, WI).  Ampicillin, potassium chloride, 
potassium phosphate (monobasic), ethylenediamine tetraacetic acid (EDTA), 
tris(hydroxymethyl)aminomethane (TRIS), N-(2-hydroxyethyl)piperazine N’-(2-
ethanesulfonic acid) free acid (HEPES), 3-(N-morpholino)-propanesulfonic acid 
(MOPS), potassium phosphate (dibasic), 5, 5’-dithiobis(2-nitrobenzoic acid), reduced 
glutathione, L-cysteine, and glutathione sulfonate were from Sigma (St. Louis, MO).  
Fosfomycin (disodium salt) was from Fluka (Ronkonkoma, NY).  Sephacryl S100 was 
from Pharmacia.  Isopropyl-β-D-thiogalactopyranoside (IPTG) and dithiothreitol (DTT) 
were from RPI (Mt. Prospects, IL).  PEG 3350 (50% solution) was from Hampton 
Research.  Hydroxylapatite, AG1-X8 resin, and Chelex 100 (Na+ form) were from 
BioRad.  DEAE Fast Flow and SP-sepharose resins were from Amersham Biosciences 
(Uppsala, Sweden).  Metals (puratronic grade) were purchased as the chloride salts from 
Alfa Aesar (Ward Hill, MA).  Tetramethylammonium hydroxide was from Acros.  AQC 
reagent kit was from Waters (Milford, ME).  Acetyl chloride, acetonitrile (HPLC grade), 
and diethyl ether were from Fisher.  Triethylphosphonoformate was from Avocado 
Research Chemicals Ltd.  Luria Broth Base (LB) was from Difco.  Sephacryl S100 was 
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from Pharmacia.  Restriction nucleases were purchased from New England Biolabs 
(Beverly, MA). 
 
Methods 
 
Cloning of PA1129 
The gene encoding the FosA from Pseudomonas aeruginosa, PA1129, was 
amplified by PCR from cosmid PMO013326 (Pseudomonas Genetic Stock Center, East 
Carolina University School of Medicine, Greenville, NC).  Primers (Life Technologies) 
were designed to incorporate NdeI and BamHI restriction sites at the 5’ and 3’ ends, 
respectively, of the coding sequence.  The PCR product was purified using the QiaQuick 
PCR purification kit (Qiagen Inc., Valencia, CA).  The purified PCR product and 
pET20b(+) DNA (Novagen, Madison, WI) were digested with the indicated restriction 
enzymes, purified by gel electrophoresis, and ligated to form the PA1129 expression 
plasmid.  DNA sequencing confirmed results. 
 
Protein expression   
An expression plasmid was used to transform E. coli BL21(DE3) cells.  A 2 L of 
fermenter was inoculated with enough bacteria from an overnight starter culture grown to 
OD600 < 1.2 to make a final density of approximately 0.01-0.03.  Bacteria were grown 
with constant agitation and aeration at 37°C to an OD600 = 0.8, and protein expression 
was induced by the addition of 0.4 mM IPTG.  Protein was allowed to express for 4 
hours.  Bacteria were harvested by centrifugation and stored at –20°C. 
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Protein purification 
Typically a bacteria pellet from 1 L of culture was resuspended 80 mL 20 mM 
Tris/HCl (pH 7.5) (buffer A) and lysed by sonication.  Cellular debris was removed by 
centrifugation (30,000 x g for 30 min), and the supernatant was dialyzed against 2 L 
buffer A.  All dialysis steps were conducted at 4°C, and all dialysis buffers contained 1 
mM DTT.  Crude lysate was passed through a 2.5 x 17 cm Fast Flow DEAE cellulose 
column equilibrated with buffer A, washed with A, and eluted with a linear gradient (20-
500 mM) of NaCl over 8 column volumes.  Fractions containing PA1129 as determined 
by the absorbance at 280 nm and SDS-PAGE were pooled and treated to remove any 
bound metal by dialysis for at least 8 hours against buffer A containing 5 mM EDTA and 
3 g Chelex 100 resin (H+ form)). This was followed by dialysis against buffer A.  Protein 
was then passed through a 1 x 16 cm HiPrep Q column (Pharmacia, Piscataway, NJ) 
using an FPLC system.  The column was equilibrated with buffer A prior to loading 
protein and was developed with a linear gradient of 0-220 mM NaCl in buffer A.  
Fractions containing PA1129 were pooled and dialyzed against buffer B [20 mM 
potassium phosphate (pH 6.8)] overnight.  Protein was then passed through a 2 x 7.5 cm 
hydroxylapatite column equilibrated with B and eluted isocratically with the same buffer.  
Fractions containing PA1129 were pooled and treated to remove any bound metal by 
dialysis for at least 8 hours against buffer C [20 mM TMAHEPES (pH 8.0)] containing 
5 mM EDTA and 3 g Chelex 100 resin (Na+ form) followed by dialysis in buffer C.  
Protein was concentrated using a nitrogen pressure cell fitted with an Amicon 10K 
molecular weight cut-off membrane and stored at –80°C. 
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Mass spectrometry of purified protein 
A solution of 25 µM protein in buffer was prepared.  A sample (5 µL) of this was 
mixed with 15 µL 0.1% trifluoroacetic acid prior to desalting with a ZipTip (Millipore) 
following the manufacturer’s protocol.  Protein was spotted on a MALDI target by 
mixing 1 µL protein solution with 1 µL sinapinic acid solution (10 mg in 1 mL elution 
solution).  The MALDI-TOF mass spectrometer was calibrated with standards spotted on 
the target prior to mass analysis of protein sample. 
 
Determination of reduced [GSH] 
Reduced [GSH] was determined using the technique of Ellman (30).  After 
dissolving GSH in buffer (typically 20 mM TMAHEPES pH 8.0) solution pH was 
adjusted to 8.0 with TMAOH.  Dilutions were prepared and 25 µL mixed with 950 µL 
200 mM Tris (pH 8.0) and 25 µL 5 mM 5, 5’-dithiobis(2-nitrobenzoic acid) [prepared in 
absolute ethanol] and the absorbance at 412 nm recorded.  Reduced [GSH] was 
calculated from Beer’s law (equation 1) using the extinction coefficient for 5-thio-2-
nitrobenzoate, 13,600 M-1cm-1. 
 
A = εbC     (1) 
 
Preparation of TMAfosfomycin 
The tetramethylammonium (TMA) salt of fosfomycin was prepared from the 
disodium salt by dissolving typically 100 mg in H2O followed by chilling on ice.  A 1.5 x 
15 cm AG50W-X8 (H+ form) column was prepared, equilibrated with H2O, and chilled to 
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4°C.  The fosfomycin solution was acidified to approximately pH 3 by addition of 6 M 
HCl and loaded immediately onto the column, which was maintained at 4°C.  
Fosfomycin (acid) was eluted isocratically with H2O into tubes containing a small 
volume of TMAOH solution.  Fractions containing fosfomycin were identified by the low 
pH of the fractions.  These were pooled and the pH adjusted to approximately 7 prior to 
lyophilization and resuspension in 20 mM TMAHEPES pH 8.0.  Solution was calibrated 
by complete enzymatic conversion to GS-fos followed by HPLC analysis. 
 
Kinetic analysis 
Activity assays relied on the detection of the free amino group of the peptide 
adduct of the antibiotic after derivatization with the fluorescent reagent 6-aminoquinolyl-
N-hydroxysuccinimidyl carbamate (AQC) and separation of the derivatives by reversed 
phase HPLC.  Typically 50-150 nM enzyme was preincubated with MnCl2 and KCl in 20 
mM TMAHEPES pH 8.0 prior to mixing with glutathione (GSH).  Kinetic reactions were 
equilibrated to 25°C and were initiated by the addition of fosfomycin 
(tetramethylammonium salt, TMAfos).  Typical reactions contained 50 µM Mn(II), 100 
mM K+, 1-100 mM GSH, and 0.1-5 mM TMAfos in a final volume of 100 µL.  After 2-5 
min, reactions were quenched by the addition of 200 µL 5% (w/v) trichloroacetic acid 
followed by vortexing and addition of 100 µL each of 0.8 M NaOH and 1 mM valine 
(internal standard).  A 5 µL aliquot was then added to 80 µL borate buffer and mixed 
with 15 µL of the AQC reagent solubilized according to manufacturer’s directions.  
Reactions were heated for 10 min at 55°C and diluted with 400 µL 50 mM NaOAc pH 
5.0 prior to injection onto a 0.046 x 25 cm Ultrasphere C-18 column (Beckman, 
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Fullerton, CA).  Samples were eluted with a linear 0-35% MeCN gradient with a flow 
rate of 1 mL/min over 15 min.  GSH-fos, GSH, and valine had retention times of 9.3, 
11.2, and 14.7 min, respectively as illustrated in Figure 11.  The ratio of product to valine 
peak areas were used to calculate product concentrations from a calibration curve 
constructed from area ratios of product:internal standard versus substrate concentration. 
 
Determination of minimum inhibitory concentration for fosfomycin 
E. coli BL21(DE3) cells were transformed with empty pET20(b) vector as well as 
vector containing PA1129.  Liquid LB cultures containing 100 µg/mL ampicillin were 
inoculated from freshly streaked LB agar plates containing ampicillin and grown at 37°C 
with shaking.  After several hours, bacteria equivalent to an OD600 = 0.02 were streaked 
on LB agar plates containing 100 µg/mL ampicillin, 30 µM glucose-6-phosphate, and 
various concentrations of fosfomycin.  Bacteria were grown 16 hr at 37°C, and growth 
was recorded. 
 
K+-free purification 
Protein was expressed and purified as described for native enzyme until after the 
HiPrepQ column.  Protein was then concentrated to 10 mg/mL and dialyzed in 20 mM 
Tris pH 7.5 containing 100 mM NaCl and 100 µM EDTA (Buffer C) containing 1 mM 
DTT.  Protein was passed through an S100 column equilibrated with buffer C and eluted 
with an isocratic gradient of buffer C.  Purity was confirmed using SDS-PAGE.  Protein 
was then dialyzed in 20 mM TMAHEPES pH 8.0 (Buffer B) plus 1 mM DTT, 3 g Chelex, 
and 5 mM EDTA followed by dialysis in buffer B.  Protein was then concentrated and 
stored in aliquots at -80°C. 
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Circular dichroism spectroscopy 
Solutions of MnCl2, KH2PO4, and protein in 20 mM MOPS pH 7.0 were passed 
through a 0.2 µM syringe filter to remove particulates.  Protein concentrations were 
determined by measuring the absorbance at 280 nm and calculating concentration using 
Beer’s Law and the extinction coefficient (native, T9V, T9S, G37E = 25,670 M-1 cm-1, 
W34A, W34AG37E = 20,030 M-1 cm-1).  Measurements were taken using a Jasco J-80 
CD spectrometer (VU Center for Structural Biology) maintained at 25°C.  Spectra were 
recorded from 190-260 nm with 1 nm steps at 5 nm/min with 2 s averaging time.  The 
instrument was autozeroed on buffer.  Concentrations in the sample cuvette were:  [E] = 
40 µM, [MnCl2] = 260 µM [K+] = 100 mM,  Similar samples containing 5 mM 
fosfomycin were also analyzed.  Data were converted to molar ellipticity (θ) using 
equation 2, where c is [E] in mM, n is the number of amino acids, and l is the cell length 
in cm, and plotted. 
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Preparation of EPR samples 
Samples consisting of 5 mM PA1129 in the presence of 500 µM Mn2+ alone or 
with 2 mM disodium fosfomycin were prepared in 20 mM HEPES pH 8.0.  Spectra were 
collected from 11700-12700 Gauss at Vanderbilt University with the assistance of Dr. Al 
Beth.  Samples of enzyme with bound metal and fosfomycin with either 100 mM K+ or 
20 mM Tl+ were also prepared.  Data for these samples as well as ENDOR spectra were 
collected by collaborators Brian Hoffman and Josh Telser (Northwestern University).  
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Deuterated samples were also prepared as follows.  TMA HEPES (pH 8.0) as well as 
MnCl2, TMAfosfomycin, and phosphonoformate were prepared, lyophilized to dryness, 
and resuspended in D2O.  Drying and resuspension was repeated.  Enzyme was 
deuterated by concentrating in a Centricon spin concentrator followed by addition of 
deuterated TMA HEPES.  This was repeated twice.  Samples containing 5 mM E, 0.5 
mM Mn++, with or without 2 mM fosfomycin or 5 mM phosphonoformate were prepared, 
frozen, and shipped on dry ice to collaborators at Northwestern University. 
 
Synthesis of phosphonoformate 
Phosphonoformate was prepared from triethylphosphonoformate by a previously 
reported method (31).  Triethylphosphonoformate (10 g, 48 mmol) was added to a 
solution of 11.42 g (285 mmol) of sodium hydroxide in 90 mL of water at 50°C.  The 
solution was heated to 90°C.  After being refluxed for 1 h, the reaction mixture was 
cooled to 20°C.  Phosphonoformate was then filtered from the reaction mixture using a 
Buchner funnel fitted with Whatman #1 filter paper.  The product was recrystallized from 
water and lyophilized to dryness.  Elemental analysis:  C:  4.83%; H:  2.71%, O:  
52.74%. 
 
Synthesis of acetyl phosphonate 
Acetyl phosphonic acid was synthesized following methods previously described 
(32, 33).  Tris(trimethylsilyl) phosphite was slowly added to a 2-fold excess of acetyl 
chloride in a flask immersed in an ice/EtOH bath.  The mixture was stirred for at least 2 h 
on ice and then stirred at room temperature overnight.  After removal of the volatile 
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silane products, the pH of the solution was adjusted to 4 with NaOH.  The reaction 
mixture was extracted with diethyl ether several times.  The aqueous layer containing the 
product was then taken to dryness by lyophilization:  1H NMR (300.1 MHz, D2O) δ 2.22 
(d, JPCH 3.72 Hz); 13C NMR (75.5 MHz, D2O) δ 30.6 (d, JCP 43.8 Hz), 228.6 (d, JCCP 
157.6 Hz). 
 
Synthesis of formyl phosphonic acid 
Synthesis of formyl phosphonic acid was attempted following a published 
protocol (34).  Briefly, nitrilotris(methylene phosphonic acid) was mixed with hydrogen 
peroxide in the presence of vanadyl sulfate catalyst.  A variety of pH and temperature 
conditions were tested. 
 
Inhibition assays 
Enzyme assays were carried out as described above.  In a typical reaction mixture, 
enzyme (60-150 nM) was incubated with 100 mM KCl, 50 µM MnCl2, and 15 mM GSH 
in 20 mM TMAHEPES (pH 8.0) at 25°C in the presence of 1, 2, 3, or 4 mM disodium 
fosfomycin and varying concentrations of phosphonoformate, acetylphosphonic acid, 
phosphonoacetic acid, or 2-carboxyethylphosphonic acid.  Reactions were quenched; 1.0 
mM valine was added as an internal standard, and the mixture was reacted with Waters 
AccQFluor reagent and analyzed by reversed-phase HPLC.  Inhibition data were 
analyzed as a Dixon plot (1/V vs [I]) to determine KI (35). 
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Inhibition by GSO3-, pyruvate, or ethyl phosphonoformate 
Glutathione sulfonate (GSO3-) (0 or 12 mM) was added to enzyme reactions 
containing 150 nM PA1129, 50 µM Mn(II), 100 mM K+, 6 mM disodium fosfomycin, 
and 7.5 or 15 mM GSH in 20 mM TMAHEPES pH 8.0.  E•Mn(II)•K+ was incubated 
with inhibitor prior to the addition of substrates.  Similar reactions containing 2 mM 
TMAfosfomycin and GSH were carried out in the presence of 5 µM ethyl 
phosphonoformate.  Reaction velocities were determined by measuring product formation 
as previously described.  Pyruvic acid was analyzed for inhibition by adding 20 mM to 
enzyme reactions which were analyzed by 31P NMR after quenching and demetallation. 
 
In vivo inhibition by phosphonoformate 
E. coli BL21 (DE3) pLysS cells were transformed with a PA1129 expression 
vector.  Cultures inoculated from a freshly-streaked LB agar plate containing 100 µg/mL 
ampicillin, 20 µg/mL glucose-6-phosphate (G6P), and 5 or 10 mg/mL phosphonoformate 
were grown at 37°C to mid-log phase.  A volume equivalent to 0.005 OD600 was used to 
inoculate a series of cultures containing similar concentrations of ampicillin, G6P, and 
phosphonoformate in addition to 5 or 10 mg/mL fosfomycin.  These cultures were grown 
for 4 h while monitoring the OD600.  As a control experiment, bacteria were also grown 
on LB/agar plates containing varying concentrations of ampicillin (0.8 – 1 mg/mL) and 5 
mg/mL phosphonoformate in the presence of G6P and chloramphenicol. 
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Titration of FosA with fosfomycin and phosphonoformate 
A solution of 0.1 µM PA1129 in the presence of 50 µM MnCl2 was prepared in 20 
mM TMAHEPES (pH 8.0) containing 100 mM KCl.  A solution of 50 µM MnCl2 in 
buffer was similarly prepared.  All solutions were filtered through a 0.2 µM filter.  
Phosphonates were added to both solutions incrementally while monitoring the change in 
fluorescence.  Measurements were made in triplicate on a SPEX Fluorolog-3 
spectrofluorimeter (Jobin Yvon Horiba, Edison, NJ) in the constant-wavelength mode.  
Solutions were excited at 275 nm (3 mm slit width), and emission measurements were 
taken at 330 nm (2 mm slit width).  After data were corrected for fluorescence of the 
buffer solution, data were averaged and fit as the absolute value of the change in 
fluorescence to equation 3. 
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Stopped-Flow Analysis of Binding Kinetics 
The PA1129 FosA incubated with MnCl2 and phosphonoformate in 20 mM 
TMAHEPES (pH 8.0) was mixed with varying concentrations of fosfomycin in an 
Applied Photophysics SX17 stopped-flow spectrometer in absorbance mode.  The change 
in absorbance at 245 nm was monitored as a function of time; 1000 data points were 
collected in 100 ms using the oversampling method.  Concentrations in the observation 
cell were as follows: 5 µM FosA, 50 µM MnCl2, 100 mM K+, 25 µM phosphonoformate, 
and 5, 10, 15, and 20 mM fosfomycin.  Data were fitted to a single exponential, floating 
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end point equation using the instrument software to obtain kobs.  The first 2 ms of data 
were omitted from the data analysis.  The off rate for fosfomycin was measured in a 
similar manner by trapping with phosphonoformate. 
 
Enolization of acetyl phosphonate 
Potassium phosphate (20 mM, pH 7.5) was deuterated by taking a 100 mM 
solution to dryness, resuspending in D2O, drying, and repeating.  Deuterated buffer was 
sparged with Ar to remove dissolved oxygen prior to sample preparation.  A solution of 
0.5 µM PA1129 in the presence of 100 mM KCl and 50 µM MnCl2 in deuterated buffer 
was incubated with acetyl phosphonate (25 mM) for several days.  A similar solution 
lacking enzyme was also prepared.  At various times, aliquots were removed, and the 1H 
NMR was recorded. 
 
Adduct formation between GSH and acetylphosphonate 
A solution of 1 µM PA1129 in deuterated, Ar-sparged KPi (20 mM, pH 7.5) 
containing 5 µM MnCl2, 25 mM GSH, and 25 mM acetyl phosphonate was allowed to 
incubate at room temperature.  A similar solution lacking enzyme was prepared.  At 
various times, aliquots were removed, demetallated with Chelex 100 resin, and analyzed 
by 1H NMR. 
 
GSH docking and minimization 
 This work was done in collaboration with Eric Dawson, Ph. D. in the lab of Terry 
Lybrand, Ph. D. at Vanderbilt University.  An initial conformation of GSH was taken 
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from coordinates found in a co-crystal structure of a porcine glutathione S-transferase 
containing GSO3- in the active site (2GSR) (36).  The GSO3- was changed to GSH and 
manually docked into the active site of FosA (1LQP) (28) using the interactive molecular 
graphics program PSSHOW (E. Swanson, University of Washington, 1995).  To allow 
favorable positioning of the GSH substrate in the enzyme's active site, a fosfomycin 
molecule bound at the entrance to the enzyme’s active site (in 1LQP) was removed and 
sidechain dihedral angles for residues K90 and Q36 were changed to the first most 
probable rotamer from a backbone-dependant amino acid rotamer library (37).  All 
crystallographic waters were retained during the manual docking steps; however, waters 
having Van der Waal's radii overlapping with atoms of manually docked GSH were 
removed prior to energy minimization calculations. The resulting structure retained a 
significant ‘droplet’ of crystallographic water molecules. Molecular mechanics 
parameters for the GSH and fosfomycin substrates were developed (see below) to enable 
energy minimization calculations following molecular docking. Partial charges for both 
substrates were generated using ab initio electrostatic potential calculations with a 6-
31G* basis set, followed by fitting to an atom-centered point charge model with the 
RESP program (38). Use of the unionized thiol form of GSH limited the need for 
development of molecular mechanics parameters for this ligand to the γ-glutamyl residue 
of GSH. The amino acid residue type (ILG) was created in the LeaP module of AMBER 
using parameters derived from methyl-glutamine (used as a model compound). 
Parameters for FosA as well as for the catalytic ion-cofactors were available in public 
databases. Hydrogen atoms were added to the enzyme-substrate complex, which was then 
refined to remove any residual bad steric interactions or backbone conformational strain 
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using a combination of limited (200 steps) steepest descents and conjugate-gradient 
energy minimization. The calculations were performed in vacuo with a distance-
dependent dielectric model, using standard AMBER all-atom potential functions in 
AMBER 8.0 (39).   
 
Molecular Mechanics Parameter Development 
 The following lists parameters and .prp files developed and utilized for energy 
minimization. 
 
------ILG - amino-terminal monomer from glutathione (GSH)------------------- 
ILG.prp 
ILG  INT  0 
 CORRECT  OMIT  DU  BEG 
 0.0 
    1 DU1  DU   M     0     0     0    0.0000    0.0000    0.0000 
    2 DU2  DU   M     1     0     0    1.0000    0.0000    0.0000 
    3 DU3  DU   M     2     1     0    1.0000   90.0000    0.0000 
    4 N    N3   M     3     2     1    1.2624  149.1681  315.3131   -0.8689 
    5 H1   H    E     4     3     2    1.0049  133.6152  120.5899    0.3395 
    6 H2   H    E     4     3     2    1.1096   83.0337  220.7611    0.3395 
    7 H3   H    E     4     3     2    1.0069  111.4414  327.2653    0.3395 
    8 CA   CT   M     4     3     2    1.4802   29.1957   65.4978    0.2825 
    9 HA   HP   E     8     4     3    1.0853  107.1225  107.8812    0.0238 
   10 C    C    B     8     4     3    1.5360  107.3531  354.0461    0.6306 
   11 O    O2   E    10     8     4    1.3392  113.4132   20.6207   -0.5382 
   12 OXT  O2   E    10     8     4    1.2029  123.8519  198.9541   -0.5382 
   13 CB   CT   M     8     4     3    1.5334  113.8678  229.1416    0.0122 
   14 HB2  HC   E    13     8     4    1.0810  108.8775  311.1876    0.0095 
   15 HB3  HC   E    13     8     4    1.0846  109.3753   68.0776    0.0095 
   16 CG   CT   M    13     8     4    1.5331  113.3891  190.4032   -0.0498 
   17 HG2  HC   E    16    13     8    1.0779  110.0078  294.9958    0.0086 
   18 HG3  HC   E    16    13     8    1.0876  109.9151   53.5195    0.0086 
   19 CD   C    M    16    13     8    1.5188  110.5419  171.8841    0.5449 
   20 OD   O    E    19    16    13    1.2217  122.4343  343.4974   -0.5536 
 
DONE 
 
STOP 
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#################################################################### 
##  Parameters for Fosfomycin and Glutathione (ILG) developed in collaboration  ## 
##    with the research group of Professor Terry Lybrand    ## 
#################################################################### 
 
------Fosfomycin ----------------------------------------------------------- 
fos.prp 
FCN  INT  0 
 CORRECT  OMIT  DU  BEG 
 0.0 
    1 DU1  DU    M      0      0     0     0.0000     0.0000     0.0000 
    2 DU2  DU    M      1      0     0     1.0000     0.0000     0.0000 
    3 DU3  DU    M      2      1     0     1.0000    90.0000     0.0000 
    4 C1     CT    M      3       2     1     0.5588  119.2199  156.2674   -0.0043 
    5 H11   HC    E       4      3     2     1.0900  126.9068  305.7325   -0.0119 
    6 H12   HC    E       4      3     2     1.0917  119.7220    97.6411   -0.0119 
    7 H13   HC    E       4      3     2     1.0911   73.0795   203.6849   -0.0119 
    8 C2     CT    M      4      3     2     1.5112   33.2379    14.9290     0.0434 
    9 H2     H1    E       8      4     3      1.0827  116.2593  184.2278   -0.0280 
   10 O3    OS    M      8      4     3    1.4686  114.6385    49.0908    -0.4633 
   11 C4    CT    M    10      8     4    1.5177   59.5838   247.7705    0.0872 
   12 H4    H2    E     11    10     8    1.0821  108.8855  253.7460   -0.0113 
   13 P      P       M    11    10     8    1.8765  124.3382  116.2854    1.0550 
   14 O2P  O2    E     13    11    10    1.5043  103.3487   74.6816   -0.8810 
   15 O3P  O2    E     13    11    10    1.5186  104.5741 313.1847   -0.8810 
   16 O1P  O2    E     13    11    10    1.5082   98.4772  194.0102   -0.8810 
 
LOOP 
C2   C4 
 
DONE 
 
STOP 
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#################################################################### 
##  Parameters for Mn2+ and Fosfomycin taken from Amber Parameter Database  ## 
##    Website - http://pharmacy.man.ac.uk/amber/     ## 
#################################################################### 
 
Mn2+ vdw parameters (from Concanavalin A study by G.M. Bradbrook et al.) 
 
MASS 
MN     55.00     0.00 
 
NONB 
MN        1.6900     0.0140 
 
----------------------------------------------------------------------------- 
Fosfomycin parameters (calix[4]arenes: PhD Thesis of Marc Baaden - 250800) 
 
MASS 
 
BOND 
CT-P  331.      1.82 
 
ANGLE 
CT-P -O2    60.       104.6     angles from gopt / force const. (Baaden) - esd 
CT-CT-P     35.       113.1             "               " 
OS-CT-P     50.       124.3             "               " 
P -CT-H2    60.       127.3             "               " 
 
DIHEDRAL 
X -CT-P -X    9           3.51           0.      3.  tpl - JPC 94 
 
NONBOND 
 
------manganese------------------------------------------------------------- 
mn.prp 
MNG  INT  0 
CHANGE OMIT DU  BEG 
 0.0 
   1 DUMM  DU  M  0  -1  -2  0.000      0.000      0.000     0.000 
   2 DUMM  DU  M  1   0  -1  1.0000    0.0000   0.0000   0.000 
   3 DUMM  DU  M  2   1   0  1.0000  90.0000  0.0000    0.000 
   4 MN        MN  M  29.683 127.561 -18.450  2.00 
 
DONE 
 
STOP 
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Generation of Mutants 
Site-directed mutagenesis was performed on the PA1129 expression plasmid 
using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA).  
Oligonucleotide primers (Life Technologies) were designed to change codon 9 from 
ACC to GTC (T9V) and TGC (T9S), codon 34 from TGG to GCG (W34A) and CAC 
(W34H), codon 37 from GGC to GAA (G37E), codon 39 from TAT to TTT (Y39F), 
codon 48 from TGC to GCC (C48A), and codon 50 from TCC to ATG (S50M) and TGC 
(S50A).  Multiple mutants W34A/G37E, W34A/G37E/S50M and 
W34A/G37E/Y39F/S50M were also created.  A disrupted K+-binding loop mutant was 
prepared by inserting RVE residues (CGC GTC GAG) between residues 93 and 94.  The 
W34A/G37E/Y39F/S50M mutant was also created in the K+-binding loop mutant 
background.  Site-directed mutagenesis was also performed on the B. subtilis FosB 
expression plasmid using primers designed to change codon 40 from TAT to TTT 
(Y40F).  Mutations were confirmed by DNA sequencing. 
 
Expression and purification of mutants 
Mutants were expressed and purified as described for native protein.  Briefly, for 
PA1129 mutants, bacteria were lysed by sonication followed by centrifugation to pellet 
debris.  Lysate was dialyzed in 20 mM Tris pH 7.5 prior to loading onto a DEAE column 
equilibrated with this buffer.  Protein was eluted with a salt gradient, and fractions 
containing PA1129 were pooled and dialyzed in 20 mM KPi pH 6.8.  Protein was passed 
isocratically through a hydroxylapatite column equilibrated with the same buffer.  
Fractions containing PA1129 were pooled and dialyzed against 20 mM TMAHEPES 
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pH 8.0 containing Chelex resin and EDTA followed by dialysis in 20 mM TMAHEPES 
pH 8.0.  For FosB, protein was passed through a DEAE column and eluted with a NaCl 
gradient prior to dialysis followed by isocratic elution from a hydroxylapatite column.  
Protein was then demetallated and passed isocratically through an S100 gel filtration 
column.  Protein was dialyzed in 20 mM HEPES pH 8.0, concentrated, and stored at        
-80°C. 
 
Kinetic analysis of mutant enzymes 
The kinetic assay for native protein was followed as described to determine 
kinetic parameters for mutants.  Briefly, enzyme was incubated with the appropriate 
metal(s) prior to addition of thiol and fosfomycin (disodium or TMA salt).  Reactions 
were quenched and derivatized with a fluorescent reagent (AQC) prior to HPLC analysis. 
 
Fluorescence titration of enzyme with glutathione 
A solution of 5 µM PA1129 in the presence of 50 µM MnCl2 and 100 mM KCl 
was prepared in 20 mM TMAHEPES (pH 8.0) which had been filtered through a 0.2 µm 
filter.  A solution of buffer containing MnCl2 and KCl was prepared similarly.  GSH was 
added to both solutions incrementally while monitoring the change in fluorescence.  
Titrations were also done in the presence of phosphonoformate.  Titration measurements 
were made in triplicate on a SPEX Fluorolog-3 spectrofluorimeter (Jobin Yvon Horiba, 
Edison, NJ) in the constant-wavelength mode.  Solutions were excited at 275 nm (3 mm 
slit width), and emission measurements were taken at 340 nm (3 mm slit width).  After 
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correction for fluorescence of buffer, data were averaged and fit to a hyperbola to obtain 
a Kd. 
 
Estimation of turnover number by 31P NMR Spectroscopy 
In typical reactions, enzyme was equilibrated with Mn(II) in 20 mM HEPES (pH 
7.5) prior to the addition of 25-150 mM GSH.  Reactions were initiated by the addition of 
25 mM fosfomycin and allowed to proceed at room temperature for several minutes to 
several hours.  Reactions were quenched by vortexing with CHCl3 followed by freezing 
on dry ice.  After thawing and centrifugation, the aqueous layer was removed to a fresh 
tube and incubated with a small amount of Chelex 100 resin (H+ form) for at least 3 hr to 
remove Mn(II), which causes a paramagnetic line broadening of the 31P signal.  Reactions 
were centrifuged to pellet the Chelex resin followed by removal of the supernatant to a 
fresh tube.  The Chelex was washed with distilled, deionized H2O, centrifuged, and the 
supernatant removed and combined with the first supernatant.  After addition of D2O, the 
proton-decoupled 31P spectra of the reactions were collected at 121 MHz.  GS-fos, 1,2-
dihydroxypropylphosphonic acid, and fosfomycin had 31P chemical shifts of 18.1, 16.9, 
and 11.1 ppm, respectively.  Following the law of conservation of mass, product and 
substrate peak heights are measured and amount of product formed calculated from the 
ratio between peak heights and total substrate used in the reaction. 
 
Purification of the FosB from B. subtilis 
Protein was overexpressed in BL21-DE3 E. coli cells grown from an 
LB/ampicillin (100 µg/mL) plate freshly streaked from a glycerol stock.  A 100 mL 
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LB/ampicillin culture was inoculated with one colony and grown overnight (typically 12 
hr at 27°C and 150 rpm).  A volume of overnight culture was added to 2 L LB containing 
ampicillin and antifoam in a 2 L fermentor to make the final OD600 = 0.006.  Bacteria 
were grown to OD600 = 0.8, when 400 mM IPTG was added to induce overexpression.  
Bacteria were grown for 4 hr, harvested by centrifugation, and cell pellets stored at -20°C 
prior to purification.  Cells were resuspended in approximately 80 mL 20 mM TRIS pH 
7.5, lysed by sonication [4 x 3 min at duty cycle 7 and output control 8], and centrifuged 
to pellet cell debris.  All dialysis was done in 2 L buffer at 4°C in the presence of 1 mM 
dithiothreitol (DTT).  Protein was dialyzed in 20 mM TRIS pH 7.5 prior to being passed 
through a 1.6 x 60 cm DEAE FastFlow column equilibrated with buffer.  Protein was 
eluted with a 20-250 mM NaCl gradient over 8 column volumes.  Fractions containing 
FosB as identified by A280 and SDS-PAGE were pooled and dialyzed against 20 mM KPi 
pH 6.8.  Protein was then passed through a 2 x 7.5 cm hydroxylapatite column 
equilibrated with buffer, washed with buffer, and eluted with an 8 column gradient of 50-
350 mM KPi.  Fractions containing FosB were pooled and dialyzed in 20 mM TRIS pH 
7.5 containing 3 g Chelex (H+ form), 100 µM EDTA, and 100 mM NaCl prior to isocratic 
elution from a Sephacryl S100 gel filtration column.  Protein was diluted in half with 
buffer and dialyzed in 20 mM TRIS pH 7.5 containing 3 g Chelex and 5 mM EDTA prior 
to dialysis in 20 mM HEPES pH 8, concentration, and storage at -80°C. 
 
Kinetic analysis of the FosB from B. subtilis 
Kinetic reactions were carried out for FosBBs in reaction mixtures containing 600 
nM enzyme, 1 mM Mg++, 0.1-10 mM fosfomycin, and 2-50 mM cysteine in 20 mM 
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HEPES pH 8.0.  Reactions were done at 25°C in 100 µL volume for sufficient time to 
allow approximately 15% product formation. Reactions were quenched and derivatized 
as previously described (see Chapter 3 Methods).  Data were fit to the Michaelis-Menten 
equation using the program Prism to obtain Km and kcat. 
 
Crystallization of the FosB from B. subtilis 
Several attempts were made to crystallize purified protein at ambient temperature 
using the hanging drop method.  Conditions were identified which produced needles and 
small crystals.  These were typically 2-4% glycerol or ethanol and 12-14% PEG 3350 in 
100 mM Tris pH 8.5.  Enzyme (5 mg/mL) was incubated with MgCl2 (10 mM) and Cys-
fos product (10 mM) prior to mixing equal volumes (2-4 µL) of enzyme solution with 
well solution on cover slides. 
 
Cloning, expression, and purification of the FosB from S. aureus 
The gene encoding the FosB protein from S. aureus was amplified from genomic 
DNA by PCR using gene-specific primers.  NdeI and EcoRI sites were added to the 5’ 
and 3’ ends, respectively.  A silent mutation (CAT to CAG) was incorporated in codon 
134 to remove an NdeI site from the coding sequence.  An expression vector was 
prepared as described for FosAPA.  This plasmid was used to transform BL21-DE3 E. coli 
cells.  Protein was expressed as described for PA1129 except after induction with IPTG 
(0.2 mM) cells were grown at 30°C for 5 hours.  Bacteria harvested from 2 L of culture 
were suspended in 100 mL 20 mM KPi pH 6.8, lysed by sonication, and the resulting 
suspension centrifuged for 30 min at 35,000 x g.  The supernatant was stirred with 
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Benzonase Nuclease (Novagen, Madison, WI) according to the manufacturer’s directions 
[50 µL Benzonase, 2 mM MgCl2, and 10 mg BSA for 2 h at 25°C], thereby reducing or 
eliminating undesired interactions of FosB with nucleic acids.  Benzonase treatment was 
followed by dialysis against 20 mM KPi pH 6.8.  All dialysis was performed at 4°C, and 
all buffers contained 1 mM DTT.  Protein was passed through a 1.6 x 60 cm SP-
Sepharose column equilibrated with buffer (20 mM KPi pH 6.8).  The column was then 
washed with buffer, and protein was eluted with a 10-500 mM NaCl gradient (in buffer) 
over 8 column volumes.  Fractions containing FosB were identified by the absorbance at 
280 nm and SDS-PAGE.  These fractions were pooled and dialyzed against buffer.  
Protein was then loaded onto a 2 x 7.5 cm hydroxylapatite column equilibrated with 
buffer and eluted with a linear phosphate gradient (20-500 mM) in buffer.  Fractions 
containing FosBSA were pooled and dialyzed against 20 mM MOPS (pH 7.0) containing 
5 mM EDTA and 3 g Chelex 100 (H+ form, 100-200 mesh) to remove protein-bound 
metal, followed by dialysis against 20 mM MOPS pH 7.0.  Protein was concentrated and 
stored at -80°C. 
 
Preliminary kinetic analysis using 31P NMR 
Enzyme incubated with Mg++ was mixed with fosfomycin and various thiol 
substrates (typically 25 mM each) for product analysis.  Reactions were quenched by 
vortexing with CHCl3 prior to mixing with D2O (20% final concentration) followed by 
analysis by proton-decoupled 31P NMR (121 MHz). 
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Kinetic analysis with L-cysteine and fosfomycin 
Preliminary assays were done in the presence of a variety of metal ions.  
Transition metals were at 50 µM, and Mg++ was at 1 mM.  Typical kinetic reactions 
contained 300 nM enzyme preincubated with 1 mM MgCl2, 0.1–10 mM fosfomycin, and 
1–80 mM cysteine in 20 mM HEPES pH 8.0.  Protein concentration was determined 
using the absorbance at 280 nm and the extinction coefficient as calculated from the 
tyrosine and tryptophan content (40) using Equation 1 with  ε = 21,280 M-1cm-1.  
Reactions were quenched, neutralized, and derivatized as described in prior to analysis by 
HPLC. 
 
Crystallization of the FosB from S. aureus 
Attempts to crystallize purified FosBSa were largely unsuccessful.  Small crystals 
were obtained in typical conditions of 12-14 % PEG 3350, 2% glycerol, 10 mM cys-fos, 
500 µM Mg, and 5 mg/mL E in 100 mM Tris pH 7.  The crystals obtained exhibited 
diffraction to only about 3 Å, and data was not collected.  Instead, further optimization 
was pursued. 
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CHAPTER III 
 
CLONING, PURIFICATION, AND CHARACTERIZATION 
OF PA1129, THE FOSA HOMOLOGUE FROM 
PSEUDOMONAS AERUGINOSA 
 
Results 
 
Purification 
The developed purification protocol produced high yields (100 mg/L culture) of 
very pure protein (Figure 10).  The molecular weight agreed with the calculated mass of 
15,114 Da.  As expected, the protein interacted well with DEAE resin, since the 
calculated pI was 6.2 (EMBL WWW Gateway to Isoelectric Point Service).  
 
Kinetic analysis 
Protein concentrations were accurately determined prior to kinetic assays by 
measuring the A280 and using the extinction coefficient 21,280 M-1cm-1 as calculated 
from the tryptophan and tyrosine content (40) and Beer’s Law.  Reactions were analyzed 
via HPLC using a calibration curve to correlate peak areas for product and internal 
standard (valine).  A typical HPLC chromatogram is shown in Figure 11. 
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Figure 10.  A.  MALDI mass spectrum of purified PA1129.  B. SDS-PAGE showing 
protein standards (first lane) and fractions containing PA1129 from a hydroxylapatite 
column.  PA1129 bands (15,114 Da) are between molecular weight markers aprotinin 
(6,894 Da) and lysozyme (19,374 Da). 
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Figure 11.  HPLC chromatogram of a typical FosA reaction mixture.  GS-fos, GSH, and 
valine have retention times of 9.3, 11.2, and 14.7 min, respectively. 
 
 
Preliminary studies indicated that PA1129 utilized Mn++ preferentially for 
catalysis and was activated in the presence of K+.  Figure 12 shows fits of kinetic data to 
determine KactK+, kcat, and Km for both substrates; table 2 lists these results as well as 
kcat/Km for substrates. 
 
Table 2.  Kinetic parameters determined for PA1129. 
KactK 
+ (mM) 
8.7 ± 1.5 
kcat (s-1) 175 ± 6 
kcat/KmFos (M-1s-1) (9.0 ± 1.4) x 105 
kcat/KmGSH (M-1s-1) (3.5 ± 0.9) x 104 
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Figure 12.  A.  Activation of PA1129 in the presence of increasing [K+].  B and C.  
Michaelis-Menten plots of steady-state kinetic data for fosfomycin (B) and GSH (C). 
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MIC determination 
The ability of PA1129 to confer resistance to fosfomycin in the biological context 
of E. coli was determined by growing bacteria transformed with a PA1129 expression 
plasmid in varying concentrations of fosfomycin.  The minimum inhibitory concentration 
(MIC) was determined as the concentration of fosfomycin at which bacteria no longer 
grew.  This could not be accurately determined for PA1129, as bacteria grew at antibiotic 
concentrations > 45 mg/mL, the saturation limit for making solid agar plates for the 
experiment.  Figure 13 shows bacterial growth on plates as well as MIC for fosfomycin 
for each protein tested.  MIC values obtained are shown in Table 3. 
 
Table 3.  MIC values obtained for the fosfomycin resistance proteins in mg/mL. 
 - G6P + G6P Kcat/KmFos (M-1s-1) 
pET 20 (control) < 0.025 < 0.025 --- 
Tn2921 > 25.6 > 25.6 (1.4 ± 0.1) x 107 
Bs_yndn 25.6 > MIC > 12.6 1 > MIC > 0.05 (4.0 ± 0.6) x 103 
PA1129 > 25.6 > 25.6 (9.0 ± 1.4) x 105 
mlr3345 0.40 > MIC > 0.20 < 0.025 (5.0 ± 0.6) x 102 
FosBSa > 25.6 0.40 > MIC > 0.20 (9.2 ± 0.1) x 103 
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Figure 13.  Bacterial growth of E. coli transformed with 1.  pET-20b or pET-20b 
containing sequences for 2.  Tn2921 3.  Bs_yndn 4.  PA1129 5.  mlr3345 6.  FosBSa.  
Plates contained 100 µg/mL ampicillin, and those on the right contained 40 µM glucose-
6-phosphate.  From the top, left to right, plates contained 0, 0.025, 0.05, 0.1, 0.2, 0.4, 1.6, 
3.2, 6.4, 12.8, and 25.6 mg/mL fosfomycin. 
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K+-free purification 
Protein eluted from the gel filtration column was of high purity (gel filtration 
chromatogram, Figure 14, and SDS-PAGE gel, data not shown).  This protein exhibited 
equivalent activity to protein purified via the previous protocol. 
 
 
 
 
 
 
 
 
Figure 14.  Chromatogram of the absorbance at 280 nm of the eluate from an S100 
column in a typical FPLC run.  PA1129 is shown as a single peak with no contaminants 
visible. 
 
 
EPR spectroscopy 
EPR spectra of PA1129 in the presence of Mn(II) was compared to the 
E•Mn(II)•fosfomycin complex (Figure 15A).  As shown previously for Tn2921, the 
addition of substrate greatly perturbs the metal coordination (29).  Structural information 
indicates that this is the result of a change in metal coordination by addition of a 
phosphonate oxygen into the coordination sphere.  Collaborators have also collected 
absorbance EPR and 31P ENDOR spectra of PA1129 with bound metal and phosphonate 
(Figure 15B and C) (41).  These results indicate that the oxirane oxygen of fosfomycin is  
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Field (T) 
 
Figure 15.  A.  Derivative EPR spectra of PA1129•Mn(II) and PA1129•Mn(II)•fos 
recorded at Vanderbilt University.  B.  Derivative EPR spectra of the same recorded by 
collaborators.  C. 35GHz Continuous wave EPR spectra taken at 2 K and 30 dB 
microwave power of 5 mM PA1129 with bound Mn(II) (500 µM), K+ (100 mM), 
fosfomycin (S), and phosphonoformate (Pf).  B and C were recorded by collaborators at 
Northwestern University. 
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also coordinated to the metal center, although distances taken from the crystal structure 
do not support this (28). 
 
Circular dichroism spectroscopy 
CD spectra of PA1129 and several mutants in the presence of Mn(II) and K+ and 
substrate are shown in Figure 16.  There were no apparent differences between native 
protein and mutants.  Also, no structural changes were apparent upon the addition of 
substsrate. 
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Figure 16.  Circular dichroism spectra of PA1129 and indicated mutants in the presence 
of Mn++ and K+ (top panel) and plus fosfomycin (bottom panel). 
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Discussion 
 The initial report of fosfomycin (6) hinted at the occurrence of a genomically-
encoded resistance element in P. aeruginosa, as the ED50 (the dose of antibiotic 
necessary to protect 50% of infected animals) was significantly higher than for other 
bacteria used in efficacy assays (with the exception of Streptococcus pyogenes).  More 
recent studies have shown that strains of P. aeruginosa are highly resistant to fosfomycin 
as compared to E. coli (Figure 17). 
 
Figure 17.  Reported MIC values (in µg/mL) for fosfomycin for various strains of E. coli, 
P. aeruginosa, and S. aureus.  Taken from (23-25, 42).  Where a range for the MIC was 
given, the average was taken. 
 
 
Indeed, our own in vitro studies indicate that the protein provides high levels of 
resistance when expressed in E. coli.  Kinetic data reveals that PA1129 falls just short of 
the superb catalytic efficiency of the plasmid-encoded homologue (TN2921) but is an 
excellent catalyst nonetheless. 
Prior to the availability of structural data for the fosfomycin resistance proteins, 
circular dichroism spectroscopy was used to characterize native enzyme as well as 
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several mutants.  In addition, electron paramagnetic resonance spectroscopy was used to 
probe the Mn(II) environment in the presence of K+, substrate, and inhibitor bound to the 
enzyme.  CD spectra indicated that native protein was well folded, with negative 
ellipticity characteristic of  α-helical content.  Addition of substrate had no significant 
effects on enzyme secondary structure.  Also, several mutants (discussed in more detail in 
Chapters V and VI) exhibited spectra similar to native protein, indicating that they are 
probably folded in a similar manner. 
EPR spectroscopy is a valuable tool for observing changes in Mn(II) coordination 
environments.  The derivative EPR spectra Mn(II) produces a signature sextet splitting 
pattern resulting from a hyperfine coupling between the electron spin and the spin (I=5/2) 
of the 100% natural abundance 55Mn nucleus (43).  The spectrum of PA1129•Mn(II)•K+ 
exhibited the six-line pattern typical of Mn++ (Figure 15A and B).  Upon addition of 
fosfomycin, this signal is almost obliterated due to line broadening.  This corresponds to a 
change in metal coordination, either through changes in ligands or coordination geometry.  
EPR absorbance spectra (Figure 15C) reveal further differences in zero field splitting 
parameters (Discussed in (41)). 
The x-ray crystal structure of PA1129 (Figure 18) was solved during the course of 
this work (28).  These results further supported a membership in the VOC superfamily as 
the βαβββ structural motif and metal binding mode are conserved.  As predicted from 
EPR studies and mechanistic details of VOC relatives, PA1129 uses its metal center to 
coordinate substrate oxygens.  A phosphonate oxygen is clearly coordinated to the 
manganese, being 2.1 Å from the metal.  It was anticipated that the oxirane oxygen would  
also coordinate to metal (20), but the distance (2.35 Å) between the atoms in the crystal
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Figure 18.  A.  Ribbon diagram of PA1129 colored by monomer.  Mn(II) and K+ ions are 
purple and yellow spheres, respectively.  B.  Enlargement of the active site showing 
metal ligands (His7, His67, Glu110) as well as fosfomycin, Arg119, Thr9, Cys48, Ser50, 
Tyr39, and Trp34.  Figure generated from 1LQP.pdb using the program PyMOL (10). 
T9 
C48 
S50 
W34 
Y39 R119 
E110 
H67 
53 
 structure was outside the accepted range for Mn(II)--O coordination.  However, detailed 
ENDOR studies (data not shown) indicate that the oxirane oxygen is coordinated with a 
longer-than-expected distance, probably due to the poor electron-donating ability of the 
oxygen (41).  Spectra indicate that, in solution, fosfomycin coordinates Mn(II) only 
through the phosphate moiety.  However, in the enzyme active site, spin density on the 
31P is reduced by transfer via 31P—C—Ooxirane—Mn(II).  This is in agreement with other 
VOC enzymes, as it serves to activate the epoxide for attack by a nucleophile, thus 
facilitating catalysis. 
Comparison of catalytic efficiency (Table 3) revealed that this value correlates 
well with MIC for fosfomycin in in vitro studies.  Although the method used does not 
allow for variations in protein expression levels, it provides an assay for analysis of 
putative fosfomycin resistance proteins.   
 
 
 
 
 
 
 
 
54 
CHAPTER IV 
 
DEVELOPMENT AND ANALYSIS 
OF POTENTIAL FOSA INHIBITORS 
 
Results 
 
Inhibition assays 
The panel of phosphonate inhibitors (Figure 9) tested were found to inhibit 
PA1129 to a varying degree depending primarily on the length of carbon chain linking 
the phosphonate and carboxyl moieties (Table 3).  Formyl phosphonic acid could not be 
successfully synthesized for testing in inhibition assays. Phosphonoformate, the proposed 
transition state analogue, was also tested for inhibition of the plasmid encoded FosA.  
Data indicate that it is a competitive inhibitor of both FosA enzymes.  Figures 19 and 20 
show Dixon plots of inhibition data.  Since lines intersect in quadrant II, it is apparent 
that the inhibitors are competitive with respect to fosfomycin. 
 
Other inhibitors 
Assays carried out in the presence of glutathione sulfonate and pyruvate produced 
insignificant inhibition at the concentrations tested. Ethyl phosphonoformate, however, 
inhibited reactions nearly as well as phosphonoformate.  These compounds were not 
pursued past preliminary tests for inhibition. 
 
 
55 
Figure 19.  Dixon plots of inhibition data of PA1129 (top) and FosA (bottom) with 
phosphonoformate (Pf). 
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Figure 20.  Dixon plots of inhibition assays of PA1129 with acetyl phosphonate (AcP) 
and phosphonoacetic acid (PAA). 
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Table 4.  Inhibition constants for a panel of phosphonates tested with PA1129. 
Compound KI (µM) 
Phosphonoacetic acid 10 ± 1 
Phosphonoformate 0.41  ± 0.09 
Acetyl phosphonate 18 ± 2 
 2-carboxyethylphosphonate > 100 
Pyruvate n.d.* 
GSO3- n.d. 
*n.d. = none detectable 
 
In vivo inhibition by phosphonoformate 
While phosphonoformate (Pf) proved to be a very effective inhibitor in vitro, it 
proved to be ineffective in lowering the MIC for fosfomycin when added to cultures of E. 
coli BL21-DE3 pLysS cells transformed with a FosA expression plasmid (Figure 21).  In 
fact, addition of Pf to cultures actually lowered the MIC for ampicillin in the absence of 
fosfomycin from 1 mg/mL to approximately 0.7 mg/mL, indicating the inhibitor may be 
acting on cells in a fosfomycin-independent manner.  The mechanism of action is not 
understood, although the molecule could be acting as an analogue of a small cellular 
phosphonate such as PEP and competitively inhibiting a variety of enzyme activities in 
the cell. 
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Figure 21.  Results of bacterial growth in the presence of varying concentrations of Pf in 
the presence of 0 (open) 5 (gray), or 10 (black) mg/mL fosfomycin. 
 
Enolate and GSH adduct formation 
In addition to being a likely FosA inhibitor, it was possible that acetyl 
phosphonate could form a 1,2-adduct with GSH in the FosA active site (Figure 22B).  
Alternatively, FosA could catalyze formation of an enolate and enhance deuterium 
incorporation in the AcP methyl group (Scheme 1).  Acetyl phosphonate in the presence 
of GSH and E•Mn(II) was monitored for the formation of a GSH-acetyl phosphonate 
adduct.  This adduct would likely not be stable enough to be isolated from a reaction 
mixture.  NMR analysis of reaction mixtures revealed that adduct was not formed to a 
measurable extent.  E•Mn(II) and AcP incubated in D2O up to several days indicates that 
FosA cannot catalyze this reaction under the conditions tested (Figure 23). 
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Figure 22.  A.  Coordination geometry of a proposed transition state in FosA.  B.  
Possible adduct of GSH and acetyl phosphonate in the FosA active site. 
 
 
 
Scheme 1.  Formation of the enolate of acetyl phosphonate showing incorporation of 
deuterium in the methyl group. 
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Figure 23.  1H NMR spectra showing incubation of acetyl phosphonate with E•Mn(II) in 
D2O (top) and in reactions lacking enzyme (bottom) for 48 hr (A), 7 days (B), and 15 
days (C).  No differences from the control were observed. 
 
Binding of substrate and Pf to FosA 
Binding of substrate or Pf to PA1129 produced a characteristic change in the A245 
(Figure 24A).  This was utilized to obtain information about their rates of binding to 
enzyme.  Although binding rates were too large to be measured directly, differences in 
the ε245 were used to obtain koff for Pf from FosA•Mn(II)•K+•Pf by mixing with an excess 
of fosfomycin (Figure 24B).  The koff for fosfomycin from FosA•Mn(II)•K+•fosfomycin 
was determined in a similar manner by mixing with Pf (Figure 24C).  Binding events 
followed single-exponential behavior, indicating that, in both cases, the phosphonate used 
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in excess successfully trapped FosA•Mn(II)•K+ upon dissociation of bound ligand.  Fits 
of the data to a single exponential gave koff values of 5 and 30 s-1 for Pf and fosfomycin, 
respectively.  
 
Steady state phosphonate binding 
Although changes in the UV spectra were useful for obtaining pre-steady state 
binding information, the enzyme concentration (5 µM) necessary to produce measurable 
spectroscopic changes was in excess of estimated dissociation constants.  However, 
changes in intrinsic protein fluorescence upon phosphonate binding were observed 
(Figure 25A), allowing the use of lower enzyme concentrations.  Accordingly, steady-
state titrations of FosA•Mn(II)•K+ with fosfomycin and phosphonoformate were carried 
out while observing fluorescence changes at 330 nm (Figure 25B).  Equilibrium 
dissociation constants of 0.74 ± 0.01 µM for fosfomycin and 0.17 ± 0.01 µM for 
phosphonoformate were obtained. 
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Figure 24.  A.  UV difference spectra of the complexes:  (---) FosA• Mn(II)•1 - FosA• 
Mn(II) (∆ε245 = -1690 M-1 cm-1) ; — FosA• Mn(II)•2 - FosA• Mn(II) (∆ε245 = -4560 M-1 
cm-1)  B.  Change in A245 upon rapid mixing of 5 µM FosA•Mn(II)•K+•2 with 10 mM 1.  
The solid line is a fit of the data to a single-exponential equation with a kobs of 5.06 ± 
0.02 s-1.  The bottom trace is the residual to the fit.  C.  Change in A245 upon rapid mixing 
of 5 µM FosA•Mn(II)•K+•1 complex with 5 mM 2.  The solid line is a fit of the data to a 
single-exponential equation with a kobs of 29 ± 3 s-1.  The bottom trace is the residual to 
the fit. 
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Figure 25.  A.  Fluorescence emission spectra of FosA•Mn(II) () and after addition of 
substrate ( ) and Pf (---).  B.  Fluorescence titrations of FosA•Mn(II)•K+ with  
fosfomycin () and Pf ().  Solid lines are fits of the data to equation 3 with dissociation 
constants of 0.74 ± 0.01 µM for fosfomycin and 0.17 ± 0.01 for Pf. 
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Discussion 
The high-resolution structure of PA1129 with bound Pf has been reported (28).  
Figure 26A shows the location of Pf with respect to the metal center and residues 
providing hydrogen-bonding interactions.  In this structure, the metal is five-coordinate.  
The angular structural parameter, τ, for describing trigonality (44) was calculated from 
metal—ligand geometries according to equation 4, where α is the angle between 
equatorial ligands and β is the angle between axial ligands. 
 
τ = (β − α) / 60                  (4) 
 
Calculations using α = 119.39° (angle between Glu110 and Pf carboxylate)  and 
β = 174.82° (average of angles between His7 and His64, His64 and phosphonate oxygen, 
and phosphonate oxygen and His7) produced a value for τ of 0.92.  This indicates nearly 
perfect trigonal bipyramidal geometry (τ = 1.0).  This is in contrast with the coordination 
of fosfomycin, which has a longer Mn(II)—Ooxirane distance, moving the ligand out of the 
inner coordination sphere. 
Structural results supported kinetic data implicating Pf as a competitive inhibitor, 
as it is bound in exactly the same position as fosfomycin (Figure 26B).  Note the 
significant movement of Tyr62 between the substrate and inhibitor complexes.  This 
motion may account for the spectral differences observed between E•Mn(II)•fosfomycin 
and E•Mn(II)•Pf and could provide a means of recognition of product by the enzyme, 
leading to its release during turn-over. 
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Figure 26.  A.  Phosphonoformate (Pf) bound in the PA1129 active site.  Mn(II) and K+ 
ions (purple and green spheres, respectively) are shown.  Metal ligands E110, H7, and 
H64 as well as T9 and S98 are shown.  Distances are in Å.  B.  Overlay of PA1129 with 
substrate or Pf bound in the active site.  Note overlay of the phosphonates and the 
difference in orientation of Tyr62.  Figure generated in PyMOL (10) from 1LQP.pdb and 
1NKI.pdb. 
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Inhibition of FosA 
Several simple phosphonates were modestly effective competitive inhibitors of 
the FosA enzyme encoded in the genome of P. aeruginosa. Phosphonoformate, acetyl 
phosphonate (AcP), and phosphonoacetate (PAA) were chosen as possible substrate or 
transition state analogues of the addition reaction based on the suggestion that the Mn(II) 
center acts as a Lewis acid to facilitate breaking of the C—O bond of the oxirane (19, 
28).  Oxirane ring-opening reactions typically occur with early transition states so that the 
geometry of the proposed five-membered chelate ring (Figure 22) is very close to that 
observed in the complex with Pf.  Indeed, analysis of inhibition data indicated that 
inhibition by Pf was competitive (data lines crossed in quadrant II) and had a reasonable 
Ki. Transition state analogue inhibitors typically bind much more tightly than the 
corresponding substrate does.  The fact that Pf binds only ∼6-fold more tightly than 
substrate may reflect the fact that the reaction has a very early transition state with little 
charge build-up on the oxirane oxygen.  Taken together, these observations suggest that 
Pf can be viewed as a minimal transition state inhibitor for FosA given that it lacks any of 
the structural elements of the second substrate GSH. 
Phosphonoacetate, with the chelate ring expanded by a methylene group, binds 
∼20 fold less tightly than Pf.  This compound resembles the structure of a very late 
transition state in which the C-O bond is almost completely broken.  Acetylphosphonate 
(AcP), has a neutral oxygen adjacent to the phosphonyl group in place of the charged 
carboxylate.  This compound has a Ki that is significantly higher than the Kd for 
fosfomycin.  AcP was of particular interest because of its potential to form an enolate 
complex, Scheme 1, or a metal-stabilized 1,2-adduct with GSH (Figure 22B) in the FosA 
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active site.  Catalysis of enolate formation by FosA is not unlikely, since other VOC 
superfamily members (e.g. extradiol dioxygenase) efficiently carry out catalysis via an 
enolate intermediate.  Although deuterium incorporation in the methyl group is observed, 
the FosA•Mn(II) complex does not promote enolate formation over and above that 
observed with Mn(II)•6H2O.  Since AcP is not a very good inhibitor of FosA, it is 
unlikely that the enolate, if formed on the enzyme, is a particularly stable or highly 
populated species.  Formation of an adduct with GSH was investigated, as it could be 
stabilized and trapped by coordination with the metal center.  No adduct was apparent in 
NMR spectra of reaction mixtures.  However, the adduct may form but not be stable 
enough to accumulate to sufficient concentration to be visible by NMR. 
It is probable that formyl phosphonic acid would inhibit FosA, but this compound 
could not be synthesized for analysis.  2-Carboxyethyl phosphonic acid, with two 
methylene groups added to the carbon chain, is presumably too long to bind well in the 
active site since it does not inhibit enzyme activity.  Glutathione sulfonate and pyruvate 
failed to inhibit PA1129 to any appreciable extent.  The anionic sulfonate may not be 
accommodated well in the active site, although it is an effective inhibitor of the soluble 
glutathione transferases.  Although pyruvate contains a carboxylate moiety which could 
presumably bind in the site typically filled by fosfomycin’s phosphate group, an 
oxyanion group (e.g. sulfate, phosphate) may be required for binding in this site. 
 
In vivo inhibition 
E. coli transformed with the expression plasmid for FosA exhibit robust resistance 
to fosfomycin.  Unfortunately, none of the inhibitors examined here were effective in 
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enhancing the efficacy of fosfomycin toward these transformants either in liquid culture 
or on agar plates.  The reason for the lack of activity in vivo is unclear but may be due to 
ineffective transport of the molecules into the cytosol of the bacterium.  The triethyl ester 
of Pf was tested for improved in vivo activity with the assumption that the esterified 
compound might enter cells more readily, where esterases would quickly cleave the ester 
bonds to form the active molecule.  It is not known if the compound enters the cell or if 
cleavage actually occurs.  These attempts at in vivo inhibition were also unsuccessful. 
 
Kinetics of Binding of Fosfomycin and Phosphonoformate 
Binding of phosphonates to PA1129 produced a characteristic change in the UV 
absorbance of the protein (Figure 24).  Compared to E• Mn(II), E• Mn(II)•fosfomycin 
produced a ∆ε245 of -1690 M-1 cm-1 and E• Mn(II)•Pf a ∆ε245 of -4560 M-1.  These 
changes in extinction coefficient were utilized in stopped-flow experiments to observe 
dissociation of fosfomycin from E• Mn(II)•fosfomycin by trapping as E•Mn(II)•Pf and 
vice versa.   
The equilibrium dissociation constant Kd for each phosphonate could not be 
measured by absorbance due to the high enzyme concentration required for these 
experiments.  In addition to the absorbance change, phosphonate binding produced a 
decrease in intrinsic protein fluorescence which could be utilized in steady state 
fluorescence titration experiments.  Interestingly, addition of Pf to the enzyme produced a 
blue shift in the emission spectrum which was not seen with fosfomycin.  The reason for 
this is unknown but could reflect minor changes in protein structure due to the transition-
state nature of the inhibitor.  Titration data revealed a dissociation constant of 0.2 µM and 
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koff of 5 s-1 for Pf, suggesting that Pf binding occurs near the diffusion limit.  A koff of 
30 s-1 and Kd of 0.7 µM are consistent with a diffusion-controlled binding of fosfomycin 
as well.  This rapid binding prevented the direct measurement of kon.  However, kon could 
be estimated from equation 5, giving koff/Kd ≈ 107 - 108 M-1 s-1. 
 
Kd = koff / kon                 (5) 
 
The one clearly measurable difference in the equilibrium binding of Pf is the 
smaller rate constant for dissociation of the bidentate chelate.  It seems evident that 
candidates for fosfomycin resistance protein inhibitors should retain this feature to 
facilitate binding to the enzymes. 
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CHAPTER V 
 
GLUTATHIONE BINDING AND ACTIVATION IN FOSA 
 
Results 
 
GSH docking and energy minimization 
After repeated attempts to identify a GSH binding site in FosA through protein 
crystallization trials using GSH, glutathione sulfonate, and GS-fosfomycin, a potential 
binding site was identified in PA1129 through manual molecular docking followed by 
energy minimization of the docked complex.  Favorable intermolecular hydrogen 
bonding interactions to the docked GSH in the model include Arg93, Lys90, Ser50, 
Tyr39, Gln36, and Trp34.  Figure 27 shows the location of GSH in a ribbon diagram of 
FosA (PA1129) as well as a diagram of hydrogen bonding interactions between GSH and 
protein. 
 
Kinetic analyses of native and mutant enzymes 
Glutathione transferases are known to use tyrosine or serine residues to assist in 
ionization of GSH during catalysis (45).  It has been suggested that cysteine residues 
might also be involved in GSH ionization.  A series of mutants was prepared and 
analyzed to identify a potential residue serving this purpose in FosA.  Although Cys48 
and Ser50 were preliminary candidates, mutation of either residue to Ala had little effect 
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on catalysis (Table 5).  The S50A mutant displayed substrate inhibition with fosfomycin.  
The equilibrium constant Ki for inhibition as calculated from equation 6 was 2.4 mM. 
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Results from the energy-minimized docked enzyme-substrate complex indicated 
that Tyr39 was in a favorable position to ionize GSH, being 3.45 and 3.48 Å from the 
unionized thiol of GSH and the C1 group of fosfomycin, respectively.  The Y39F mutant 
displayed a 10-fold reduction in turnover and 100-fold decrease in catalytic efficiency.  
Mutagenesis of the corresponding residue in FosB, also a thiol-utilizing enzyme, had 
similar effects on catalysis. 
W34A and W34H mutants were also prepared and analyzed for activity since 
Trp34 was within hydrogen bonding distance to GSH in the model.  W34A exhibited a 
substantial increase in KmGSH.  The W34H mutant, however, had recovered native 
kinetics.  These mutations had minimal effect on fosfomycin kinetics.  All kinetic results 
are summarized in Table 5. 
 
 
72 
Table 5.  Kinetic parameters for selected proteins. 
 
 kcat (s-1) kcat/Kmthiol (M-1s-1) kcat/Kmfos (M-1s-1) KdGSH (µM) 
M1-1 GSTa 18 ± 2 1.1 x 105 n.a. 26 ± 3 
PA1129 FosA 180 ± 6 (4.1 ± 0.8) x 104 (9.0 ± 1.4) x 105 130 ± 30 
C48A 177 ± 8 (1.3 ± 0.3) x 104 (1.6 ± 0.3) x 106  
S50A 134 ± 2 (6.2 ± 0.4) x 104 (9.1 ± 5.3) x 105  
Y39F 14 ± 2 (8.7 ± 1.0) x 102 (1.0 ± 0.6) x 105  
W34A 32 ± 3 (2.0 ± 0.4) x 102 (1.3 ± 0.3) x 104  
W34H 30 ± 4 (5.4 ± 1.1) x 103 (1.1 ± 0.3) x 104 100 ± 20 
B. subtilis FosB 4.8 ± 0.3 122 ± 37 (4.0 ± 0.6) x 103  
Y40F 0.02    
n.a.:  not applicable   
a.  Taken from (46).  
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Figure 27.  A.  Ribbon diagram of FosA (PA1129) with GSH shown in the docked 
position.  B.  Diagram of residues participating in hydrogen-bonding with GSH.  The 
position of the GSH thiol relative to Tyr39 and fosfomycin C1 is indicated. 
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Figure 28.  Plots of kinetic data for C48A (A), S50A (B), and Y39F (C). 
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Figure 29.  Plots of kinetic data for W34A (A), W34H (B), and FosBBs (C). 
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Fluorescence titration of enzyme with GSH 
Addition of GSH to E•Mn(II) produced a characteristic decrease in intrinsic 
protein fluorescence (Figure 30A).  Interestingly, this change was lost upon pre-
incubation of E•Mn(II) with phosphonoformate (Figure 30B).  Titration of PA1129 with 
GSH revealed that the fosfomycin resistance proteins have equilibrium dissociation 
constants for GSH similar to the unrelated canonical GSH transferases (Table 5 and 
Figure 31A).  Results from molecular docking indicated hydrogen bonding could occur 
between Trp34 and the C-terminal carboxyl oxygen of GSH.  Attempts were made to 
measure the dissociation constant for GSH for the W34A mutant.  However protein 
precipitation at relatively low [GSH] precluded an accurate determination of KdGSH for 
this mutant. The W34H mutant, featuring an imidazole NH group, has potential to serve 
as a hydrogen-bond donor.  Compared with the W34A mutant, functional rescue was 
observed in W34H to near-native levels of GSH binding affinity (Figure 31B). 
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Figure 30.  A.  Fluorescence scans of  PA1129•Mn•K and --- + GSH upon excitation 
 at 275 nm.  B. Fluorescence scans of PA1129•Mn•K•Pf () and PA1129•Mn•K•Pf  
plus GSH (). 
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Figure 31.  Relative change in intrinsic protein fluorescence at 340 nm upon GSH 
titration of native (A) and W34H (B). 
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Discussion 
 
Glutathione transferases 
Many studies have provided information on GSH binding by the soluble or 
canonical GSH transferases (36, 45).  Unfortunately, the FosA proteins, although they are 
efficient GSH transferases, share no sequence similarity with any of these enzymes.  A 
third class of GSH transferases, which are trimeric, membrane-bound enzymes involved 
in cellular detoxication and other mechanisms, are also unrelated to FosA.  As a result, 
none of the information resulting from years of research on these proteins was 
particularly useful in determining a mechanism of GSH binding and activation in FosA. 
 
Potential GSH binding site 
A potential mode of GSH binding was identified by manual docking of GSH into 
the active site of PA1129 followed by energy minimization of the resulting complex.  
Docking was initially influenced by only a few pieces of data.  Early studies of FosA 
indicated that GSH was added to C1 of fosfomycin (47), indicating the sulfur must be 
positioned near this atom.  Also, conservation of Tyr39 in FosA and FosB enzymes as 
well as kinetic studies of the Y39F mutant (and Y40F in FosB) indicated this residue 
might play a primary role in thiol ionization.  Based on these points, the GSH sulfur was 
localized between the ionizing group and fosfomycin C1.  Finally, the W34A mutant 
displayed a 10-fold increase in KmGSH, indicating it could be involved in hydrogen 
bonding and thus binding affinity of the substrate.  Attempts were made to provide a 
potential for hydrogen bonding with Trp34 in the docked complex.  The complex was 
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considered minimized after only 200 steps (20 steps of steepest descent followed by 180 
steps of conjugate gradient descent) as no improvement in potential energy scores was 
obtained upon further minimization. 
 
GSH ionization 
FosA proteins contain several active site residues which could serve to facilitate 
GSH ionization prior to catalysis.  Ser50 and Cys48, both likely candidates from early 
analysis of the active site containing fosfomycin, seemed to play minor roles in catalysis, 
as alanine mutants had activity comparable to native enzyme.  Interestingly, the S50A 
mutant displayed substrate inhibition with relatively low levels of fosfomycin.  This type 
of inhibition typically results from the binding of a second substrate molecule to E•S, 
producing an inactive ternary complex (S•E•S).  Figure 32 shows the location of a second 
molecule of fosfomycin bound to PA1129 in the crystal structure.  While no direct 
contacts with Ser50 are visible, it is interesting that the residue is in two conformation.  
Removal of the serine hydroxyl may allow for binding in solution of a molecule of 
fosfomycin to the enzyme in a manner similar to that observed in the crystal structure. 
The reason for this inhibition remains unclear. 
Tyr62 and Tyr100, both conserved throughout the fosfomycin resistance protein 
family, have previously been indicated in phosphonate binding (48).  In addition to these 
strictly conserved tyrosines, Tyr39 seemed a possible candidate for participation in thiol 
ionization due to its location in the FosA active site in our model and its conservation in 
the FosB cysteine-utilizing proteins.  A recent study probing the ability of random FosA 
mutants to grow on fosfomycin-containing media revealed that Tyr39 was essential for  
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Figure 32.  Diagram showing a second molecule of fosfomycin bound at the entrance of 
the PA1129 active site.  Note the two conformations of Ser50.  Ordered water molecules 
and Mn(II) ions are shown as blue and purple spheres, respectively.  Distances are shown 
in Å.  Distance from Lys90 and the nearest phosphonate oxygen is 2.82 Å (omitted for 
clarity).  Figure prepared from 1LQP.pdb using the program PyMOL.  
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resistance, as no mutations were tolerated at this position (49).   Available data from 
canonical GSH transferases indicates that first-sphere hydrogen bonding to the thiol can 
lower the pKa, thus facilitating catalysis.  Second-sphere interactions provided by protein 
residues can further lower the pKa by enhancing the stability of the resulting thiolate (45).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33.  Hydrogen bonding interactions between (from top to bottom) fosfomycin and 
GSH sulfhydryl, GSH sulfhydryl and Tyr39, and Tyr39 to Tyr128.  Distances between 
heavy atoms are shown in Å. 
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Such a second-sphere hydrogen bond between Tyr39 and Tyr128, which is conserved in 
the FosA proteins, is consistent with a role of Tyr39 in ionization (Figure 33).  Indeed, a 
10-fold reduction in activity was observed for the Y39F mutant.  While this reduction is 
not as great as seen in equivalent mutants of canonical GSH transferases, activation of 
substrate in fosfomycin resistance proteins by the metal center increases its 
electrophilicity and could decrease the effect of thiolate anion formation on catalysis. 
 
GSH binding 
In our model for substrate binding, residues forming intermolecular hydrogen 
bonds to the docked GSH include Arg93, Lys90, Ser50, Tyr39, Gln36, and Trp34 (Figure 
27).  None of these residues are conserved in the other classes of resistance proteins with 
the exception of Tyr39 in the FosB proteins.  Only one residue, Gln36, is modestly 
conserved in FosX as a lysine, which is capable of supplying the NH2 functionality. This 
could explain why FosX mutants capable of catalyzing the FosA reaction do so only at 
high [GSH] (Fillgrove and Armstrong, unpublished data).  Of the GSH interacting 
residues, Lys90 is particularly interesting as it ion-pairs with a terminal carboxyl of GSH.  
This seems essential for GSH binding, as canonical glutathione transferases consistently 
retain a positive residue for this purpose.   
Although FosA proteins apparently arose from a convergent evolutionary 
pathway with respect to the canonical GSH transferases, many similarities in GSH 
binding are apparent.  Initial comparison with crystal structures of alpha, pi, mu, and 
sigma GSH transferases reveals a comparable extended conformation of GSH (Figure 
34).  A primary determinant of GSH recognition and binding conserved in the canonical
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Figure 34.  Ribbon diagrams of 1GSQ (salmon), 2GSR (blue), 2GST (orange), and 
PA1129 (purple) containing bound 1-(S-glutathionyl)-2,4-dinitrobenzene, glutathione 
sulfonate, (9S, 10S)-9-(S-glutathionyl)-10-hydroxy-9-10-dihydrophenanthrene, and 
glutathione, respectively, in stick representation.  In PA1129, K+ and Mn(II) are shown as 
yellow and purple spheres, respectively.  Figures generated using PyMOL (10).    
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enzymes involves coordination of both GSH carboxylate functionalities by enzyme 
residues, typically Trp and Lys (36).  This appears in FosA as well, since, in addition to 
Gln and Arg residues, a Trp and Lys are used to supply hydrogen bonds to the substrate 
(Figure 27).  One significant difference from the canonical enzymes involves the number 
of contacts between enzyme and substrate.  These proteins typically have a dozen or so 
interactions, while in our model only half that many were identified. This could partially 
account for the approximately 5-fold decrease in GSH affinity exhibited by PA1129 as 
compared to a GSH transferase from the mu class (Table 5). 
Attempts were made to study the effects of removing the hydrogen bond supplied 
by Trp34 to GSH by mutation to Ala.  While a value for the GSH equilibrium 
dissociation constant could not be determined for this mutant, circular dichroism 
spectroscopy (Chapter III) indicates that the protein is folded in a manner similar to 
native enzyme.  The W34H mutant exhibited GSH affinity similar to native protein, and 
there was a recovery in KmGSH.  In addition to our results, recent functional resistance 
assays of random mutant enzymes showed a requirement for Trp34 and for a positively 
charged residue at position 90 (49), indicating these residues may be critical for GSH 
binding to occur. 
Addition of GSH to PA1129 produced a characteristic change in intrinsic protein 
fluorescence (Figure 30A).  However, when protein was pre-incubated with 
phosphonoformate, a transition-state analogue, the fluorescence change upon GSH 
binding was lost (Figure 30B).  This indicates that phosphonate binding could poise the 
enzyme for GSH binding and catalysis.  As bacteria must respond quickly to attack by 
antibiotics, using fosfomycin binding to prime the enzyme for GSH, which is always 
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present in the cell, could lead to more efficient catalysis and therefore a better chance of 
survival. 
Titration of PA1129 with GSH revealed that the enzyme has a KdGSH <<KMGSH.  
This could indicate that the E•GS- complex may not reach equilibrium due to turnover 
being faster than substrate binding (Scheme 2).  Attempts were made to measure rates of 
GSH binding via changes in intrinsic protein fluorescence as observed in steady state 
experiments.  However, changes were too rapid to obtain values for kobs, supporting a 
very rapid establishment of GSH binding equilibrium.  An alternate experiment to 
measure binding was attempted by monitoring changes in absorbance at 239 nm, as this 
is a signature of thiolate formation (50).  Unfortunately, no changes could be observed in 
direct binding assays or in competition experiments of E•Mn(II)•K+•GSH plus GSO3-.  
Fosfomycin binds to FosA at near the diffusion limit, (48) and subsequent turnover is 
very rapid.  Since the off-rate for fosfomycin is much slower than turnover, GSH binding 
cannot reach equilibrium (Scheme 2).  This lack of equilibrium produces the observed 
discrepancy between Kd and Km. 
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Scheme 2.  Proposed steps in the mechanism of PA1129. 
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CHAPTER VI 
 
ROLE OF THE K+-BINDING LOOP AND SELECTED ACTIVE 
SITE RESIDUES IN THE EVOLUTION OF THE FOSFOMYCIN RESISTANCE 
PROTEINS 
 
 
Results 
 
Conserved threonine provides important hydroxyl moiety 
FosA Thr9 is interesting in that it is conserved in FosA and X proteins but not in 
the FosB family.  X-ray crystal structures of FosA revealed that Thr9 is within hydrogen 
bonding distance of the oxirane oxygen of fosfomycin (Figure 35) (28).  T9V and T9S 
mutants were prepared to analyze the role of the hydroxyl functionality in substrate 
binding and catalysis.  Results show that the valine mutant, which lacks the hydroxyl, has 
only slightly impaired substrate affinity (Figure 37 and Table 6) but an almost 100-fold 
decrease in catalytic efficiency.  Both are restored in the serine mutant (Figure 37 and 
Table 7). 
 
K+-binding loop 
Early studies of the plasmid-encoded FosA revealed that it was activated by 
monovalent cations (27), but the role of K+ in this activation has remained poorly 
understood.  To more fully elucidate how activation occurs, analyses of substrate binding 
and catalysis of native protein in the absence of small monovalent ions and a mutant 
protein containing a disrupted, non-functional binding loop were carried out (Tables 6 
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Figure 35.  Active site of PA1129 showing bound Mn(II) [purple sphere] and fosfomycin.  
Side-chains of His7, Glu110, Arg119, and Thr9 are shown in stick representation.  
Distances are shown in Å.  Figure generated from 1LQP.pdb using PyMOL (10). 
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Glu110 His67 
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and 7; Figure 39).  Results show that fosfomycin binding in the mutant and for native 
enzyme in the absence of K+ is identical to native in the presence of K+.  Turnover 
supported by the non-functional binding loop mutant is similar to that of native enzyme 
in the absence of K+; this is 100-fold lower than native enzyme with bound K+. 
 
Reciprocal FosA and X mutants 
Although several active site residues overlay in superpositions of FosA and FosX 
crystal structures, several important differences in the active sites are readily apparent 
(Figure 41).  For example, Tyr39, conserved in FosA proteins, is a Phe in FosX.  FosX 
Met57 projects a bulky sulfur into the active site, which is a much smaller serine in FosA.  
FosX Glu44, the proposed active-site base which activates water for hydrolysis of 
fosfomycin, is a glycine (Gly37) in FosA.  Reciprocal mutants of these residues were 
prepared in PA1129 and mlr3345 to study the effects on catalytic ability as well as 
reaction selectivity (thiol transferase vs. hydrolase).  Trp34 appeared to block a G37E 
mutation, so this residue was converted to Ala to create the W34A/G37E double mutant.  
Several multiple mutants were also prepared to study the collective effects of the mutated 
residues.  These include W34A/G37E/S50M and W34A/G37E/Y39F/S50M.  Reciprocal 
mlr3345 FosX mutants include E44G and E44G/F46Y/M57S.  A mutant designed to 
incorporate tryptophan at a structurally-equivalent location as compared to FosA was 
prepared, but the mutant appeared to be misfolded (Fillgrove and Armstrong, 
unpublished data).  Results of kinetic analyses are recorded in Table 7. 
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Figure 36.  Plots of kinetic data for T9V (A), T9S (B). 
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Figure 37.  Plots of change in fluorescence upon titration of T9V (top) and T9S (bottom) 
with fosfomycin. 
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Figure 38.  Plots of the change in fluorescence upon titration of PA1129 with fosfomycin 
(top) and phosphonoformate (bottom) in the absence of K+. 
 
 
 
 
0 1000 2000 3000 4000 5000 6000
0
100
200
300
400
500
[Pf] (nM)
R
e
l.
!
F
lu
o
re
s
c
e
n
c
e
0 2500 5000 7500 10000 12500 15000
0
100
200
300
400
500
600
[Fos] (nM)
R
e
l.
!
F
lu
o
re
s
c
e
n
c
e
93 
 
 
 
Figure 39.  K+-loop mutant fosfomycin kinetic results (top) and relative change in protein 
fluorescence upon fosfomycin binding (bottom). 
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Figure 40.  Relative change in intrinsic protein fluorescence upon titration of 
E•Mn(II)•K+•GSH with phosphonoformate. 
 
 
Table 6.  Comparison of equilibrium binding constants for fosfomycin and 
phosphonoformate for PA1129 and mutants. 
 
 KdFos (nM) KdPf (nM) 
Native 730 ± 8  
T9V    790 ± 140  
T9S 510 ± 50  
K+-loop mutant 250 ± 44  
Native, no K+ 580 ± 40  65 ± 21 
Native, no K, + GSH  140 ± 10 
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Figure 41.  Overlay of active site residues from PA1129 (colored by atom) with M. loti  
FosX (pink).  Mn(II) is shown as a purple (or pink) sphere.  Numbers in pink  
correspond to FosX; those in black to FosA. 
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Figure 42.  A.  Plots of fosfomycin (left) and GSH (right) kinetic  data for the 
W34AG37E mutant.  B and C.  31P NMR spectra of reaction mixtures showing catalysis 
by W34A/G37E/S50M and W34A/G37E/Y39E/S50M, respectively.  Fosfomycin 
resonance is seen at 11.1 ppm; GS-Fos is at 18.0. 
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Table 7.  Turnover numbers for native and mutant enzymes for both FosA and X 
activities. 
 
 kcatFosA (s-1) kcatFosX (s-1) KmFos (µM) KmGSH (mM) 
PA1129 180 ± 6 ND* 190 ± 30 5.0 ± 0.7 
G37E 0.3 ± 0.04 ND   
W34A 32 ± 3 ND 1500 ± 340 160 ± 30 
W34A/G37E 2.0 ± 0.3 ND 280 ± 230 83 ± 12 
S50A 134 ± 2 ND 76 ± 42 2.2 ± 0.1 
W34A/G37E/S50M 0.46 ND   
W34A/G37E/Y39F/S50M 0.0004 ND   
mlr3345 0.006 0.15± 0.02   
E44G 0.0001 0.0002   
E44G/F46Y/M57S 1.4 ND   
*No detectable activity 
 
MIC determination for mutant proteins 
 The minimum inhibitory concentration for fosfomycin for each mutant protein 
expressed in E. coli was determined by growing transformed bacteria on varying 
concentrations of fosfomycin.  Plates are shown in Figure 44; data are listed in Table 9. 
 
Promiscuity 
Early studies of FosB proteins followed by discovery of the mlr3345 FosX protein 
revealed that, unlike the FosA proteins, which showed a high preference for GSH, these 
proteins were less selective in their choice of nucleophile (Tables 7 and 8) (22).  The role 
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of K+ in FosA in determining reaction selectivity was analyzed by comparing turnover 
numbers for catalysis using cysteine or GSH in the presence and absence of K+ (Figure 
43).  Results are shown in Table 8.   
 
A  B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43.  31P NMR spectra of the reaction of PA1129 with L-cysteine and fosfomycin 
in the presence (A) and absence (B) of K+.   
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Table 8.  Comparison of turnover numbers for catalysis by FosA and B with different 
thiols. 
 L-Cysteine GSH CoA 
FosBSa kcat (s-1) 5.0 0.06 0.02 
PA1129 kcat (s-1) [+K+] 6.9 180 -- 
PA1129 kcat (s-1) [-K+] 0.1 1.0 -- 
 
 
Table 9.  MIC values for fosfomycin for various PA1129 mutants. 
Protein MIC (mg/mL) 
W34A > 20 
W34H > 20 
G37E ≈ 2.5 
W34A/G37E ≈ 10 
W34A/G37E/S50M < 1.25 
W34A/G37E/Y39F/S50M < 1.25 
K+-loop mutant > 20 
W34A/G37E/Y39F/S50M in K+-loop mutant background 5 < MIC < 10 
T9S > 20 
T9V > 20 
Y39F > 20 
100 
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Figure 44.  LB-agar plates showing growth of PA1129 mutants.  A.  Clockwise from a 
are E. coli transformed with expression plasmids for T9S, T9V, K+-loop mutant, W34A, 
Y39F, and W34H expression plasmids.  B.  Counter-clockwise from a, E. coli 
transformed with W34A/G37E, W34A/G37E/S50M, W34A/G37E/Y39F/S50M, 
W34A/G37E/Y39F/S50M in the K+-mutant background, and G37E expression plasmids. 
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Discussion 
 
Conserved threonine provides important hydroxyl moiety 
It has been hypothesized that FosA Thr9 hydroxyl aids in protonation of 
fosfomycin during ring-opening.  Interestingly, this residue is not conserved in the FosB 
proteins, which could partly explain their poor catalytic abilities.  A recent study of FosA 
mutants functional in an in vitro resistance assay revealed strong preference for a 
hydroxyl moiety, either from Thr or Ser, at position 9 (49).  Our own mutagenesis 
supports the importance of a hydroxyl moiety at this position, as the T9S mutant restores 
native activity lost by the T9V enzyme (Table 7).   It would be interesting to investigate 
activity of a FosB mutant containing threonine at position 9.  If this residue is indeed 
important in increasing catalytic efficiency, it could indicate that the FosB proteins have 
developed an alternate, albeit less-effective, means of supplying a proton to fosfomycin 
during catalysis.  Consequently, adding a threonine could improve efficiency of these 
proteins.  Why this seemingly important residue would not be retained during evolution is 
not understood. 
 
Phosphonate binding in the presence of thiol 
Although phosphonate binding to FosA had been studied in the presence and 
absence of K+, it was not known if the presence of GSH affected phosphonate binding.  
Titration of PA1129•Mn(II)•K+•GSH with Pf revealed that presence of GSH had no 
effect on changes in protein fluorescence or the equilibrium dissociation of phosphonate 
(Figure 40).   
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K+-binding loop 
A unique property of FosA proteins is the truncation of one strand of the 
conserved βαβββ structural motif, resulting in the formation of a potassium binding loop 
(28).  Sequence alignments reveal the conservation of Ser94, the only residue to contact 
potassium through its side-chain, in FosA and FosX proteins (Figure 45).  In fact, 
alignments show that the binding loop could have arisen from a simple three-residue 
deletion in the evolution of FosA proteins.  A putatively non-functional binding loop 
mutant was prepared by inserting RVE residues into the FosA loop sequence.  While 
structural information is not available to conclusively show that the mutant fails to bind 
K+, preliminary assays indicate that the mutant shows little, if any, activation by K+ 
(Brown and Armstrong, unpublished data).  Alternatively, assays were carried out using 
native protein in the absence of small monovalent ions.  Analyses of kinetic and 
fosfomycin binding assays revealed that while substrate affinity was unaffected, a severe 
loss in turnover occurred.  This is indicative of the occurrence of non-productive 
substrate binding.  Crystal structures have revealed that fosfomycin is oriented in the 
FosA active site with the negative phosphonate toward the K+.  Structures of the protein 
in the presence of phosphate, phosphonoformate, and sulfate all support the presence of a 
favorable oxyanion binding site in this location (28, 48).  However, in the absence of K+, 
or with a mutant incapable of binding K+, substrate binding could occur in alternate 
manners.  In fact, analysis of FosX structures show product, sulfate, or citrate binding in 
the opposite manner as fosfomycin in the FosA structure (Fillgrove and Armstrong, 
unpublished data and Figure 45).  Key interactions—coordination to the metal center and 
hydrogen bonding between Thr9 and Arg119 and substrate—occur in both structures. 
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Figure 45.  A.  Overlay of FosA and FosX (blue) active sites showing bound substrate 
(FosA) and product (FosX).  Mn++ ions are shown in purple, and K+ ion is yellow.  Note 
the difference in orientation of the phosphonates.  B.  Local sequence alignment showing 
residues involved in coordination of the K+ ion in FosA in red. 
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An obvious difference is the presence of K+ in FosA.  Developing the ability to 
coordinate a positive ion and thus eliminate non-productive binding events would 
certainly have allowed FosA proteins to proceed toward catalytic perfection. 
 
Reciprocal FosA and X mutants 
A series of reciprocal mutants of PA1129 and mlr3345 were prepared and 
analyzed for FosA (GSH transferase) and FosX (hydrolase) activity.  The PA1129 W34A 
mutant has been discussed (Chapter V).  The W34A/G37E mutant showed a severe 
decrease in catalytic activity and corresponding increase in KmGSH.  In fact, limitations of 
the assay used prevented an accurate determination of KmGSH.  Instead, a Lineweaver-
Burk analysis was used to estimate the parameter.  The G37E mutant was not analyzed 
except for a preliminary kcat determination.  Neither the W34A/G37E/S50M or the 
W34A/G37E/Y39E/S50M mutants displayed hydrolase activity, and the GSH transferase 
activity was severely depressed.   
 
MIC determination for mutant proteins 
 In vivo resistance assays revealed that some mutations to PA1129 had little effect 
on the ability to confer resistance to fosfomycin in E. coli (Table 9).  However, the G37E 
single mutant and any multiple mutant containing G37E show depressed resistance to 
fosfomycin.  Since the kinetic efficiency of these mutants is not very high, it is not 
surprising that resistance would be low.  Interestingly, although the W34A mutant 
exhibits low catalytic activity and reduced GSH binding, it seems to retain sufficient 
activity to provide resistance in vivo. 
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Promiscuity and evolution 
As proteins evolve, they must gain catalytic activity at the expense of substrate 
diversity.  Steps to gain insight into the evolution of the fosfomycin resistance proteins 
have shown limited success.  However, it appears that FosX and FosB proteins, which are 
less catalytically proficient than the FosA proteins, are also inherently more promiscuous 
(Tables 7 and 8).  Mlr3345, the least active fosfomycin resistance protein, catalyzes the 
addition of nucleophiles, both water and GSH, to fosfomycin in addition to an as yet 
uncharacterized native activity.  Other FosX proteins which have become more proficient 
in catalyzing fosfomycin hydrolysis (e.g. lmo1702) lack the ability to act as a thiol 
transferase.  The modestly active FosB proteins developed in Gram positive bacteria to 
catalyze the addition of L-cysteine to fosfomycin.  They show no hydrolase activity but 
also show low levels of catalysis with other cellular thiols, even one (GSH) which is not 
present in their native organisms.  FosA, the most evolutionarily-advanced class of 
fosfomycin resistance proteins, shows a strong preference for GSH as thiol but can utilize 
the related cysteine, albeit not very efficiently.  Interestingly, binding of K+ by FosA 
dramatically changes the promiscuity ratio to only about a 10-fold preference for GSH 
over cysteine, indicating that acquisition of a cation binding loop played a significant role 
in the evolution of the FosA proteins (Table 8).  
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CHAPTER VII 
 
STUDIES OF FOSB HOMOLOGUES FROM STAPHYLOCOCCUS AUREUS 
AND BACILLUS SUBTILIS 
 
Results 
 
Purification of the FosB proteins 
The purification protocol for Bs_yndn protein was changed from previous 
methods (Wang and Armstrong, unpublished data) to improve purity.  Purification of the 
FosB from S. aureus (FosBSa) successfully produced respectable yields of purified, active 
enzyme.  As expected from the calculated pI of 8.51 (EMBL WWW Gateway to 
Isoelectric Point Service), protein interacted well with the cation exchange resin. 
 
 
Figure 46.  MALDI mass spectrum of purified FosB from S. aureus.  The molecular 
weight as calculated from primary sequence is 16,637 Da. 
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Kinetic analysis of FosBSa with L-cysteine and fosfomycin 
 Preliminary assays revealed that, like the protein from B. subtilis, the S. aureus 
FosB preferred Mg++ for catalysis (Figure 47).  The protein also displayed kinetics very 
similar to the B. subtilis protein (Table 10). 
 
 
 
 
 
 
 
 
 
Figure 47.  Metal ion preference as determined by relative product (Cys-fos) formation.  
Reactions contained 50 µM transition metal or 1 mM Mg++, 100 mM K++, 15 mM 
cysteine and fosfomycin, and 23 µM protein in 10 mM MOPS pH 7.0. 
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Figure 48.  Results of Michaelis-Menten plots of kinetic data for FosB from Bacillus  
subtilis (A) and Staphylococcus aureus (B).  
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Table 10.  Kinetic parameters for FosB proteins from S. aureus and B. subtilis. 
 kcat (s-1) Kmfos (µM) kcat/Kmfos 
(M-1s-1) 
Kmcys (mM) kcat/Kmcys 
(M-1s-1) 
S. aureus 0.98 ± 0.04 130 ± 20 (7.7 ± 1.3) x 103 6.0 ± 1.2 160 ± 34 
B. subtilis 4.8 ± 0.3 1190 ± 152 (4.0 ± 0.6) x 103 40 ± 12 120 ± 40 
  
Sequence alignments of FosB proteins with the FosA proteins revealed a 
conserved tyrosine which was investigated as a potential thiol ionizing residue (Appendix 
A).  Evidence from an energy-minimized complex of GSH and PA1129 indicated that the 
residue was in an ideal position with respect to fosfomycin to activate GSH.  The Y40F 
mutant of the FosB from B. subtilis was prepared by site directed mutagenesis, expressed, 
and purified.  A preliminary kinetic analysis revealed that the mutant displayed severely 
depressed activity (kcat = 0.016 s-1).  Further evidence from the PA1129 Y39F mutant 
supports the notion that residue is in fact a common catalytic residue among the thiol-
utilizing fosfomycin resistance proteins. 
 
Promiscuity of the FosB proteins 
Previous studies (Bernat and Armstrong, unpublished data) showed that FosBBs 
was capable of catalyzing the addition of a variety of thiols (Figure 49) to fosfomycin, 
although not very efficiently.  Substrate analysis of FosBSa revealed that it too was a 
promiscuous enzyme, with L-cysteine being the preferred substrate (Figure 49, Table 11) 
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Figure 49.  Thiols analyzed as FosB substrates.  1.  L-cysteine.  2.  Glutathione.  3.   CoA. 
 
 
 
 
 
 
 
 
 
 
Figure 50.  31P NMR spectra showing results from incubations of FosBSa with, from left 
to right, L-cysteine, GSH, and CoA showing formation of Cys-fos, GS-fos, and CoA-fos 
at 18.6, 18.1, and 18.3 ppm, respectively.  The fosfomycin resonance is seen at 11.2 ppm. 
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Table 11.  Turnover numbers for FosBSa catalyzed addition of thiols to fosfomycin as 
estimated by 31P NMR. 
 
 L-Cysteine GSH CoA 
kcat (s-1) 5.0 0.06 0.02 
 
Protein crystallography 
Several attempts have been made to crystallize the FosB proteins.  Some crystals 
were obtained (Figure 51), but diffraction was poor. 
 
Figure 51.  Left:  Crystals of FosBSa in 10% PEG 3350, 2% glycerol, 100 mM TRIS pH 
7.0.  Right:  Crystals of FosBBs in 14% PEG 3350 and 3% isopropanol and 100 mM TRIS 
pH 8.5. 
 
MIC for fosfomycin in E. coli 
The ability of the genomic fosfomycin resistance proteins to confer resistance in 
vivo has been approximated by determining MIC values for fosfomycin for E. coli 
transformed with plasmids expressing the resistance proteins (See Chapter III and Table 
112 
12).  Both FosB proteins produce respectable resistance in E. coli in the absence of the 
uptake inducer G6P.  However, in the presence of G6P, resistance is quite poor.  
 
Table 12.  MIC values for fosfomycin (mg/mL) provided to E. coli transformed with 
expression plasmids for the indicated FosB protein.  
 
 - G6P + G6P 
B. subtilis FosB 12.8 < MIC < 25.6 0.05 < MIC < 0.10 
S. aureus FosB > 25.6 0.20 < MIC < 0.40 
 
 
 
Discussion 
 
Kinetic analysis of FosBSa with L-cysteine and fosfomycin 
Analysis of the FosB homologue from S. aureus revealed that it was a modestly 
active cysteine transferase specific for fosfomycin.  The enzyme prefers Mg++ as its metal 
cofactor, which is similar to the homologous FosB protein from B. subtilis. 
 
Promiscuity of the FosB proteins 
The FosB proteins exhibit activity with a variety of thiol substrates, but their 
promiscuity is limited to thiol transferase reactions.  No hydrolase activity towards 
fosfomycin was observed.  Since no structural information exists for the FosB proteins, it 
is difficult to make many conclusions about how thiol promiscuity occurs. 
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Protein crystallography 
Although attempts to crystallize the fosfomycin resistance proteins have 
generated high-resolution structures of PA1129 in the presence of metal, substrate, and 
inhibitor as well as structures of the plasmid-encoded FosA and several FosX proteins, no 
structure has been obtained for a FosB.  The proteins do not crystallize readily by either 
vapor diffusion methods or under oil.  Vapor diffusion trays yield poor results, generating 
crystals having low resolution diffraction and, in some cases, mosaicity.  The proteins are 
not very amenable to NMR structural studies because their dimeric nature raises the 
effective molecular weight to over 30 kDa.  Perhaps cloning another FosB homologue 
will enable a determination of structure if the new protein crystallizes more readily. 
 
MIC for fosfomycin in E. coli 
FosB proteins confer surprisingly poor resistance to fosfomycin when tested in in 
vivo assays using E. coli transformed with expression plasmids.  The fact that these 
proteins prefer L-cysteine as a thiol donor, which is not readily available in E. coli, could 
explain their poor activity.  The resistance which is seen probably results from the ability 
of the FosB proteins to utilize GSH in the absence of cysteine.  
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CHAPTER VIII 
 
CONCLUSIONS 
 
PA1129 has been shown to be a very efficient fosfomycin resistance protein of 
the FosA class, being a GSH transferase highly specific for fosfomycin.  Like the 
plasmid-encoded protein, it prefers Mn(II) for catalysis and is activated by monovalent 
ions such as K+.  The protein has been structurally characterized via EPR and circular 
dichroism spectroscopy as well as x-ray crystallography.  It retains the paired βαβββ 
structural motifs characteristic of the VOC superfamily and utilizes its metal center in a 
similar manner to bind substrate and facilitate catalysis. 
Early crystal structures of PA1129 indicated that small phosphonates might bind 
and effectively inhibit fosfomycin resistance proteins.  Results reported here have 
established a stereoelectronic basis for the design of effective inhibitors of fosfomycin 
resistance proteins.  The development of inhibitors that are effective in vivo is an 
attractive avenue for enhancing the efficacy of fosfomycin toward pathogens that harbor 
either plasmid or genomically encoded resistance proteins.  Understanding substrate 
binding and catalysis can also aid in explanation of how the FosA proteins have become 
so catalytically efficient.   
Evolution of the fosfomycin resistance proteins remains poorly understood.  It is 
likely that FosX proteins developed from a promiscuous progenitor, since the nucleophile 
(water) is present at 55 M, a concentration far higher than other cellular nucleophiles.  
FosB proteins, which are more closely related to the progenitor than the FosA proteins, 
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could have developed the ability to utilize cysteine as a nucleophile in bacteria lacking 
GSH.  Development of a K+-binding loop and the ability to utilize GSH resulted in highly 
proficient FosA enzymes.  The K+ could serve to withdraw electron density from the 
metal center, making it more electrophilic and thus more reactive.  Evidence reported 
here indicates it enhances catalysis by facilitating substrate binding.  Essentially every 
mutant studied in attempts to more fully understand the FosA mechanism exhibited 
dramatic decreases in catalytic efficiency.  This supports the notion that FosA enzymes 
have evolved to a state of near catalytic perfection, as any structural perturbation 
produces a protein with less activity. 
The FosA proteins appear to have evolved a GSH binding site through convergent 
evolution when compared to the canonical GSH transferases.  Many similarities, 
including critical hydrogen bonding interactions with the γ-glutamyl portion of the 
molecule, seem to have arisen.  However, neither class of GSH transferase shows any 
cross-reactivity with electrophilic substrates utilized by the other class (e.g. fosfomycin, 
CDNB).  Experiments to further validate the FosA GSH binding site are on-going.  
Much remains to be learned about the FosB proteins, including analysis of various 
mutants (especially residue 9) and structural determinations.  However, these results have 
conclusively shown that FosB proteins efficiently catalyze the addition of L-cysteine to 
fosfomycin in a Mg++-dependant manner.  Mutagenesis suggests that, like the FosA 
proteins, FosB enzymes utilize an active-site tyrosine (Y40 in the Bacillus protein) to 
assist in ionization of the thiol.  Also, the FosB proteins exhibit less stringent 
requirements for thiol substrates, being able to utilize GSH and CoA in addition to 
cysteine.   
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Future Work 
A large body of knowledge has been collected regarding the FosX fosfomycin 
resistance proteins.  This includes a variety of crystal structures as well as an array of 
mutants.  More work remains to be done to elucidate structural features of FosA and X 
proteins which determine substrate specificity and catalytic efficiency.  The same can be 
said for the FosB proteins, whose structure and means of substrate binding remain 
elusive.  Many intriguing questions remain regarding the evolution of these proteins.  
Why did only the FosA class develop a monovalent ion binding loop?  How do the FosB 
proteins bind the alternate substrate CoA?  Can GSH binding be improved in the FosX 
proteins by directed evolution?  On-going research is attempting to answer these and 
other questions. 
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APPENDIX 
A1.  CLUSTAL W (1.81) Multiple Sequence Alignment 
 
 
Consensus key 
* - fully conserved residue   . - conservation of weak groups 
: - conservation of strong groups    - no consensus 
 
 
B_anthracis_FosB  -MLQGINHICFSVSNLEKSIEFYQKILQAKLLVKG-------RKLAYFDLNG- 
BS_yndn           MEIKGINHLLFSVSHLDTSIDFYQKVFGAKLLVKG-------RTTAYFDMNG- 
S_aureus_FosB     -MLKSINHICFSVRNLNDSIHFYRDILLGKLLLTG-------KKTAYFELAG- 
LMO_ATCC          -MISGLSHITLIVKDLNKTTAFLQNIFNAEEIYSSGDKTFSLSKEKFFLIAG- 
LMO_EGD           -MISGLSHITLIVKDLNKTTTFLREIFNAEEIYSSGDQTFSLSKEKFFLIAG- 
B_melitensis      -MVQGLSHMTFIVRDLDRMEEILTTVFDARRVYDSGAETFSLSKERFFLIGNG 
mlr3345           -MIEGLSHMTFIVRDLERMTRILEGVFDAREVYASDTEQFSLSREKFFLIGD- 
C_botulinum       -MIERISHITFVVKNLDKTTQLFKELFNAKZVYYSGEKKHFLFKERFFIVGS- 
P_fluorescens     -MLTGLNHLTLAVTDLDSSLAFYRDVLKLRVEAT-------WDAGAYLSLPG- 
PA1129            -MLTGLNHLTLAVADLPASIAFYRDLLGFRLEAR-------WDQGAYLELGS- 
TN2921            -MLQSLNHLTL-VSDLQKSVTFWHELLGLTLHAR-------WNTGAYLTCGD- 
consensus         -ml-glnHitf-VrdLeksi-fy-dif-akll-----------k-ayf-lag- 
 
 
B_anthracis_FosB  ---LWIALNVEEDIPRNE-IKQSYTHMAFTVTNEALDHLKEVLIQNDVNILP 
BS_yndn           ---IWLALNEEPDIPRND-IKLSYTHIAFTIEDHEFEEMSAKLKRLHVNILP 
S_aureus_FosB     ---LWIALNEEKDIPRNE-IHFSYTHIAFTIDDSEFKYWHQRLKDNNVNILE 
LMO_ATCC          ---LWICIMEGDSLQER-----TYNHIAFQIQSEEVDEYTERIKALGVEMKP 
LMO_EGD           ---LWICIMEGDSLQEQ-----TYNHIAFRIQSEEVDEYIERIKSLGVEIKP 
B_melitensis      KEPIWIATMEGEPLPTR-----TNNHVAFKIANNEYEAYLKRIRALGLEVRE 
mlr3345           ---IWVAIMQGEKLAER-----SYNHIAFKIDDADFDRYAERVGKLGLDMRP 
C_botulinum       ---QWIAVMEDANILNR-----TYHHIAFKISNSDVDNYLDKIKTLNLELKP 
P_fluorescens     ---LWLCLSLDPKRHPEP—-AADYTHYAFSIGAADFPLFVQLLRAANVQEWR 
PA1129            ---LWLCLSREPQ-YGGP—-AADYTHYAFGIAAADFARFAAQLRAHGVREWK 
TN2921            ---LWVCLSYDEARQYVPPQESDYTHYAFTVAEEDFEPLSQRLEQAGVTIWK 
consensus         ---lWial-eee-I--------aytHiAF-i---efd-w--rlk-lgv-I-p 
 
 
B_anthracis_FosB  GRERDERDQRSLYFTDPDGHKFEFHTGTLQNRLEYYKEDKKHMTFYI---- 
BS_yndn           GRERDERDRKSIYFTDPDGHKFEFHTGTLQDRLRYYKQEKTHMHFYDETAF 
S_aureus_FosB     GRVRDIRDRQSIYFTDPDGHKLELHTGTLENRLNYYKEAKPHMTFYK---- 
LMO_ATCC          ERPRVQGEGRSIYFYDFDNHLFELHAGTLEERLKRYHE------------- 
LMO_EGD           ERPRVEGEGRSIYFYDFDNHLFELHAGTLEERLKRYHE------------- 
B_melitensis      GRSRVPGEGQSIYFYDDDNHMFELHTGTLDERLKRYGQGR----------- 
mlr3345           PRPRVEGEGRSIYFYDDDNHMFELHTGTLTERLARKAKGLEAAQ------- 
C_botulinum       PRRRVSGEGYSIYFYDYDNNLFELHTETLEKRLASYTKIDNI--------- 
P_fluorescens     DNR---SEGASFYFLDPDGHKLEAHVGDLASRLAACRQKPYAGMGFFNEP- 
PA1129            QNR---SEGDSFYFLDPDGHRLEAHVGDLRSRLAACRQAPYAGMRFAD--- 
TN2921            QNK---SEGASFYFLDPDGHKLELHVGSLAARLAACREKPYAGMVFTSDEA 
consensus         -r-r---eg-SiYF-DpDghkfElHtgtL--RL--yk--------y----- 
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